{"content":"<li class=\"n-box-item date-title\" data-end=\"1529380799\" data-start=\"1529294400\" data-txt=\"Monday, December 23, 2019\">Monday, June 18, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3364746\" data-ts=\"1529357823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCMI\" target=\"_blank\">NCMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364746-after-hours-gainers-losers-06-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (06/18/2018)</a></h4><ul>     <li><b>Top gainers:</b>&nbsp;<a href='https://seekingalpha.com/symbol/NCMI' title='National CineMedia, Inc.'>NCMI</a>&nbsp;<font color='green'>+5.2%</font>. <a href='https://seekingalpha.com/symbol/SYNL' title='Synalloy Corporation'>SYNL</a>&nbsp;<font color='green'>+4.1%</font>. <a href='https://seekingalpha.com/symbol/NEW' title='Puxin'>NEW</a> <font color='green'>+3.9%</font>. <a href='https://seekingalpha.com/symbol/LPI' title='Laredo Petroleum Holdings, Inc.'>LPI</a>&nbsp;<font color='green'>+2.0%</font>. <a href='https://seekingalpha.com/symbol/AVLR' title='Avalara'>AVLR</a> <font color='green'>+1.2%</font>.</li>     <li><strong>Top Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/PAGS' title='PagSeguro Digital Ltd.'>PAGS</a> <font color='red'>-6.7%</font>. <a href='https://seekingalpha.com/symbol/DEA' title='Easterly Government Properties'>DEA</a>&nbsp;<font color='red'>-4.2%</font>.&nbsp;&nbsp;<a href='https://seekingalpha.com/symbol/KCAP' title='KCAP Financial'>KCAP</a>&nbsp;<font color='red'>-3.4%.&nbsp;</font><a href='https://seekingalpha.com/symbol/REDU' title='RISE Education Cayman Ltd'>REDU</a>&nbsp;<font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a>&nbsp;<font color='red'>-2.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364746\" data-linked=\"After Hours Gainers / Losers (06/18/2018)\" data-tweet=\"$NCMI $NCMI $SYNL - After Hours Gainers / Losers (06/18/2018) https://seekingalpha.com/news/3364746-after-hours-gainers-losers-06-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364746-after-hours-gainers-losers-06-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364727\" data-ts=\"1529354745\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBSV\" target=\"_blank\">OBSV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364727-obseva-launches-4_75m-share-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ObsEva launches 4.75M-share stock offering</a></h4><ul><li>ObsEva (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a>) <a href=\"https://www.streetinsider.com/Corporate+News/ObsEva+SA+%28OBSV%29+Launches+4.75M+Share+Follow-on+Public+Offering/14317766.html\" target=\"_blank\">commences </a>a public offering of 4.75M shares of common stock. Underwriters over-allotment is an additional 712.5K shares. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364727\" data-linked=\"ObsEva launches 4.75M-share stock offering\" data-tweet=\"$OBSV - ObsEva launches 4.75M-share stock offering https://seekingalpha.com/news/3364727-obseva-launches-4_75m-share-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3364727-obseva-launches-4_75m-share-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364719\" data-ts=\"1529353848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVE\" target=\"_blank\">VIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364719-viveve-medicals-cmrf-technology-shows-positive-effect-in-women-sui-shares-up-12-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viveve Medical&#39;s CMRF technology shows positive effect in women with SUI; shares up 12% after hours</a></h4><ul><li>Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>) is up&nbsp;<font color='green'>12%</font>&nbsp;after hours on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17194827-viveve-reports-positive-six-month-data-stress-urinary-incontinence-feasibility-study\" target=\"_blank\">announcement</a> of positive six-month data on the use of its cryogen-cooled monopolar radiofrequency &#40;CMRF&#41; platform to treat women with stress urinary incontinence &#40;SUI&#41;.</li><li>At month 6, treated women experienced a 73% reduction in SUI versus baseline as measured by one-hour pad weight test, the planned primary endpoint of its two upcoming LIBERATE studies.</li><li>The responder rate, as determined by a reduction in pad weight, at month 6 was 83%.</li><li>The company will host a conference call tomorrow, June 19, at 8:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364719\" data-linked=\"Viveve Medical&#39;s CMRF technology shows positive effect in women with SUI; shares up 12% after hours\" data-tweet=\"$VIVE - Viveve Medical&#39;s CMRF technology shows positive effect in women with SUI; shares up 12% after hours https://seekingalpha.com/news/3364719-viveve-medicals-cmrf-technology-shows-positive-effect-in-women-sui-shares-up-12-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3364719-viveve-medicals-cmrf-technology-shows-positive-effect-in-women-sui-shares-up-12-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364691\" data-ts=\"1529350958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMI\" target=\"_blank\">KMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364691-kinder-morgan-buy-after-trans-mountain-sale-to-canada-wells-fargo-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kinder Morgan a Buy after Trans Mountain sale to Canada, Wells Fargo says</a></h4><ul>     <li>Kinder Morgan (<a href='https://seekingalpha.com/symbol/KMI' title='Kinder Morgan, Inc.'>KMI</a> <font color='green'>+2%</font>) is higher after Wells Fargo <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11893852/kinder-morgan-is-a-buy-after-pipeline-sale-to-canadian-\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform with a $20 price target, saying the sale of its Trans Mountain pipeline and related infrastructure to the Canadian government removes the ongoing overhang of uncertainty in Canada and improves KMI's balance sheet and leverage.</li>     <li>Proceeds from the sale should help KMI achieve a 4.5x leverage by the end of 2018, which should remain unchanged throughout 2019, as part of the company's commitment to reducing leverage over the longer term, the firm says.</li>     <li>Wells also thinks KMI could announce new organic projects that would make its growth story more visible, including a potential second Permian-to-Gulf Coast gas pipeline or a potential sale of its carbon dioxide business, which is the largest transporter of carbon dioxide in North America.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364691\" data-linked=\"Kinder Morgan a Buy after Trans Mountain sale to Canada, Wells Fargo says\" data-tweet=\"$KMI - Kinder Morgan a Buy after Trans Mountain sale to Canada, Wells Fargo says https://seekingalpha.com/news/3364691-kinder-morgan-buy-after-trans-mountain-sale-to-canada-wells-fargo-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3364691-kinder-morgan-buy-after-trans-mountain-sale-to-canada-wells-fargo-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364687\" data-ts=\"1529349943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364687-sycamore-partners-said-to-be-interested-in-gamestop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sycamore Partners said to be interested in GameStop</a></h4><ul><li>Sycamore Partners is one of the PE firms interested in GameStop (<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color='green'>+6.8%</font>), according to a Reuters exclusive.</li><li>GameStop has hired a financial adviser to help it with the sales process.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364682-gamestop-spikes-report-pe-interest\" target=\"_blank\">GameStop spikes on report of PE interest</a> (June 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364687\" data-linked=\"Sycamore Partners said to be interested in GameStop\" data-tweet=\"$GME - Sycamore Partners said to be interested in GameStop https://seekingalpha.com/news/3364687-sycamore-partners-said-to-be-interested-in-gamestop?source=tweet\" data-url=\"https://seekingalpha.com/news/3364687-sycamore-partners-said-to-be-interested-in-gamestop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364685\" data-ts=\"1529349443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCE.A\" target=\"_blank\">FCE.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364685-forest-city-realty-jumps-14-on-reports-talks-brookfield-restart\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forest City Realty jumps 14% on reports that talks with Brookfield restart</a></h4><ul><li>Forest City Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/FCE.A' title='Forest City Realty Trust, Inc. Cl A'>FCE.A</a>)<font color='green'> jumps as much as 14%</font>&nbsp;after<a href=\"https://www.bloomberg.com/news/articles/2018-06-18/forest-city-realty-is-said-to-restart-deal-talks-with-brookfield\" target=\"_blank\"> Bloomberg reports</a> that the company has restarted talks with Brookfield Asset Management(<a href='https://seekingalpha.com/symbol/BAM' title='Brookfield Asset Management Inc.'>BAM</a> <font color='red'>-0.3%</font>) regarding for a deal with a potential price close to a $25-$25.50-per-share range that had been discussed in March.</li><li>The news comes three months after Forest City said it would be better off going it alone because the bids it received were too low.</li><li>FCE.A touched $22.76 this afternoon. On March 23, the day after FCE.A announced it ended talks with potential suitors, shares fell 6.5% to close at $19.72.&nbsp; It's 52-week high of $26.30 was reached on Sept. 11, 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364685\" data-linked=\"Forest City Realty jumps 14% on reports that talks with Brookfield restart\" data-tweet=\"$FCE.A $FCE.A $BAM - Forest City Realty jumps 14% on reports that talks with Brookfield restart https://seekingalpha.com/news/3364685-forest-city-realty-jumps-14-on-reports-talks-brookfield-restart?source=tweet\" data-url=\"https://seekingalpha.com/news/3364685-forest-city-realty-jumps-14-on-reports-talks-brookfield-restart\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364683\" data-ts=\"1529349100\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPCO\" target=\"_blank\">TPCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364683-tronc-closes-l-times-sale-to-change-name-back\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tronc closes L.A. Times sale; to change name back</a></h4><ul>   <li>Billionaire investor Dr. Patrick Soon-Shiong has <a href=\"https://www.bizjournals.com/losangeles/news/2018/06/18/soon-shiong-completes-purchase-of-la-times.html\" target=\"_blank\">closed a $500M purchase</a> of the <i>Los Angeles Times</i> and <i>San Diego Union-Tribune</i> and other local papers from Tronc (<a href=\"http://seekingalpha.com/symbol/TRNC\" target=\"_blank\">TRNC</a> <font color='green'>+3.3%</font>).</li>    <li>He's named Normal Pearlstine executive editor of the <i>Times.</i></li>    <li>The closing ends a troubled chapter in the newspaper's ownership under Tronc, including labor strife and accusations of management interference. Tronc had acquired the <i>Times</i> and other regional California papers in 2000 for $8.3B.</li>    <li>With the divestment complete, Tronc (TRNC) is <a href=\"https://twitter.com/media_ink/status/1008784142585167874\" target=\"_blank\">changing its name back</a> to Tribune Publishing, the <i>New York Post</i> reports.</li>    <li>That change was set up a month ago and was just waiting on the sales to close, Keith J. Kelly says.</li>    <li>Tribune Publishing <a href=\"https://seekingalpha.com/news/3187045-tribune-publishing-becoming-tronc-moving-nasdaq\" target=\"_blank\">rebranded and re-symboled itself</a> two years ago this month, aiming the name \"Tronc\" at \"Tribune online content\" with an eye to a more digital future. The company transferred its listing to Nasdaq from the NYSE along the way.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364683\" data-linked=\"Tronc closes L.A. Times sale; to change name back\" data-tweet=\"$TPCO - Tronc closes L.A. Times sale; to change name back https://seekingalpha.com/news/3364683-tronc-closes-l-times-sale-to-change-name-back?source=tweet\" data-url=\"https://seekingalpha.com/news/3364683-tronc-closes-l-times-sale-to-change-name-back\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364680\" data-ts=\"1529348309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LFIN\" target=\"_blank\">LFIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364680-technology-top-5-gainers-losers-of-2_55-pm-06-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (06/18/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/PCYG' title='Park City Group, Inc.'>PCYG</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/NNDM' title='Nano Dimension Ltd ADR'>NNDM</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CDLX' title='Cardlytics, Inc.'>CDLX</a> <font color='green'>+12%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='red'>-11%</font>. OIBR-C <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3364680\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (06/18/2018)\" data-tweet=\"$LFIN $LFIN $PCYG - Technology - Top 5 Gainers / Losers as of 2.55 PM (06/18/2018) https://seekingalpha.com/news/3364680-technology-top-5-gainers-losers-of-2_55-pm-06-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364680-technology-top-5-gainers-losers-of-2_55-pm-06-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364679\" data-ts=\"1529348265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HDP\" target=\"_blank\">HDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364679-hortonworksplus-4_4-on-partnership-expansions-microsoft-google\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hortonworks +4.4% on partnership expansions with Microsoft, Google</a></h4><ul><li>           Hortonworks (NASDAQ:<a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a>) <a href=\"https://seekingalpha.com/pr/17194377-hortonworks-extends-collaboration-microsoft-drive-big-data-workloads-azure\" target=\"_blank\">announces</a> renewing and extending its relationship with Microsoft to help enterprises move big data workloads to the cloud. </li><li> Customers can deploy Hortonworks Data Platform, DataFlow, and DataPlane Service natively on Microsoft Azure. Customers can also use Microsoft Azure HDInsight, which is a fully managed service powered by Hortonworks&rsquo; Data Platform. </li><li> Hortonworks also <a href=\"https://seekingalpha.com/pr/17194323-hortonworks-google-cloud-expand-partnership-accelerate-big-data-analytics-cloud\" target=\"_blank\">expands its partnership</a> with Google Cloud, which further optimizes Hortonworks Data Platform and DataFlow for Google Cloud Storage. </li><li> Hortonworks shares are&nbsp;<font color='green'>up 4.4%</font>&nbsp;to $19.95. &nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3364679\" data-linked=\"Hortonworks +4.4% on partnership expansions with Microsoft, Google\" data-tweet=\"$HDP - Hortonworks +4.4% on partnership expansions with Microsoft, Google https://seekingalpha.com/news/3364679-hortonworksplus-4_4-on-partnership-expansions-microsoft-google?source=tweet\" data-url=\"https://seekingalpha.com/news/3364679-hortonworksplus-4_4-on-partnership-expansions-microsoft-google\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364676\" data-ts=\"1529347207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPL\" target=\"_blank\">LPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364676-lg-displayminus-4_6-on-morgan-stanley-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LG Display -4.6% on Morgan Stanley downgrade</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.streetinsider.com/Downgrades/Morgan+Stanley+Downgrades+LG+Display+%28LPL%29+to+Equalweight/14316213.html\" target=\"_blank\">downgrades</a> LG Display (NYSE:<a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a>) from Overweight to Equal Weight.</li><li>               LG Display shares are&nbsp;<font color='red'>down 4.6%</font>&nbsp;to $9.08. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3364676\" data-linked=\"LG Display -4.6% on Morgan Stanley downgrade\" data-tweet=\"$LPL - LG Display -4.6% on Morgan Stanley downgrade https://seekingalpha.com/news/3364676-lg-displayminus-4_6-on-morgan-stanley-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3364676-lg-displayminus-4_6-on-morgan-stanley-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364673\" data-ts=\"1529346711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOMO\" target=\"_blank\">MOMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364673-momo-dips-on-standpoint-research-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Momo dips on Standpoint Research downgrade</a></h4><ul><li>        Standpoint Research <a href=\"https://www.streetinsider.com/Downgrades/Standpoint+Research+Downgrades+Momo+Inc.+%28MOMO%29+to+Hold/14316797.html\" target=\"_blank\">downgrades</a> Momo (NASDAQ:<a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a>) to Hold.</li><li>               Momo shares are&nbsp;<font color='red'>down 0.9%</font>&nbsp;to $53.10. Shares are&nbsp;<font color='green'>up 3.1%</font>&nbsp;in the past week,&nbsp;<font color='green'>43.7%</font>&nbsp;in the past month, and&nbsp;<font color='green'>47.6%</font>&nbsp;YTD. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3364673\" data-linked=\"Momo dips on Standpoint Research downgrade\" data-tweet=\"$MOMO - Momo dips on Standpoint Research downgrade https://seekingalpha.com/news/3364673-momo-dips-on-standpoint-research-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3364673-momo-dips-on-standpoint-research-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364672\" data-ts=\"1529346620\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SURF\" target=\"_blank\">SURF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364672-surface-oncology-clears-resistance-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Surface Oncology clears resistance, up 14%</a></h4><ul><li>Thinly traded recent IPO Surface Oncology (<a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology'>SURF</a> <font color='green'>+14.1%</font>) clears resistance at ~$15 on more than double normal volume, albeit on turnover of only 732K shares.</li><li>The company develops cancer treatments that target the tumor microenvironment. Last week, the company announced that licensee Novartis had initiated a Phase 1 study of SRG373 in a range of cancers.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363237-surface-oncology-announces-launch-early-stage-study-srf373\" target=\"_blank\">Surface Oncology announces the launch of an early-stage study of SRF373</a> (June 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364672\" data-linked=\"Surface Oncology clears resistance, up 14%\" data-tweet=\"$SURF - Surface Oncology clears resistance, up 14% https://seekingalpha.com/news/3364672-surface-oncology-clears-resistance-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3364672-surface-oncology-clears-resistance-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364671\" data-ts=\"1529346562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHT\" target=\"_blank\">DHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364671-tanker-stocks-dht-frontline-teekay-tankers-surge-on-wells-fargo-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tanker stocks DHT, Frontline, Teekay Tankers surge on Wells Fargo upgrade</a></h4><ul>     <li><a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11894765/wells-fargo-opecs-production-increase-will-benefit-tank\" target=\"_blank\">Oil tanker stocks are uniquely positioned</a> to take advantage of a likely increase in oil production and a potentially significant boost from new fuel regulations as part of IMO 2020, Wells Fargo says as it upgrades DHT&nbsp;Holdings (<a href='https://seekingalpha.com/symbol/DHT' title='DHT Holdings, Inc.'>DHT</a> <font color='green'>+8%</font>), Frontline (<a href='https://seekingalpha.com/symbol/FRO' title='Frontline Ltd.'>FRO</a> <font color='green'>+8.2%</font>) and Teekay Tankers (<a href='https://seekingalpha.com/symbol/TNK' title='Teekay Tankers Ltd'>TNK</a> <font color='green'>+9.4%</font>) to Outperform from Market Perform.</li>     <li>An increase in trading inefficiencies/frictions should be a positive for product tanker ton-miles, especially from storage opportunities and longer ton-miles via LSFO (sulphur fuel oil) from the U.S. Gulf coast, says Wells analyst Michael Webber.</li><li>The firm raises stock price targets for DHT to $7 from $5, for FRO to $7 from $5.30 and TNK to $2 from $1.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364671\" data-linked=\"Tanker stocks DHT, Frontline, Teekay Tankers surge on Wells Fargo upgrade\" data-tweet=\"$DHT $DHT $FRO - Tanker stocks DHT, Frontline, Teekay Tankers surge on Wells Fargo upgrade https://seekingalpha.com/news/3364671-tanker-stocks-dht-frontline-teekay-tankers-surge-on-wells-fargo-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3364671-tanker-stocks-dht-frontline-teekay-tankers-surge-on-wells-fargo-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364670\" data-ts=\"1529346010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTC-USD\" target=\"_blank\">BTC-USD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364670-afternoon-rally-in-cryptos\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Afternoon rally in cryptos</a></h4><ul><li>There's no particular piece of news out there, but the price of Bitcoin (<a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>) jumped more than $300 over the past couple of hours, now&nbsp;<font color='green'>ahead 4.5%&nbsp;</font>for the session at $6,751.</li><li>Ether (<a href='https://seekingalpha.com/symbol/ETH-USD' title='Ethereum USD'>ETH-USD</a>)&nbsp;<font color='green'>+4.3%</font>, Ripple (<a href='https://seekingalpha.com/symbol/XRP-USD' title='XRP USD'>XRP-USD</a>)&nbsp;<font color='green'>+3.1%</font>, Bitcoin Cash (<a href='https://seekingalpha.com/symbol/BCH-USD' title='Bitcoin Cash USD'>BCH-USD</a>)&nbsp;<font color='green'>+5.2%</font>, Litecoin (<a href='https://seekingalpha.com/symbol/LTC-USD' title='Litecoin USD'>LTC-USD</a>)&nbsp;<font color='green'>+3.6%</font>.</li><li>Judging by the price action, cryptos may have been left for dead by many, but adoption continues. Earlier today, <a href=\"https://seekingalpha.com/news/3364621-square-gets-new-york-state-cryptocurrency-license\" target=\"_blank\">the NYDFS issued a</a> \"BtiLicense\" to Square, giving residents of the Empire State the ability to buy and sell Bitcoin through Square's Cash App.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/BTLLF' title='Interbit Ltd.'>OTCPK:BTLLF</a> <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>, <a href='https://seekingalpha.com/symbol/ETH-USD' title='Ethereum USD'>ETH-USD</a>, <a href='https://seekingalpha.com/symbol/XRP-USD' title='XRP USD'>XRP-USD</a>, <a href='https://seekingalpha.com/symbol/BCH-USD' title='Bitcoin Cash USD'>BCH-USD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3364670\" data-linked=\"Afternoon rally in cryptos\" data-tweet=\"$BTC-USD $BTC-USD $ETH-USD - Afternoon rally in cryptos https://seekingalpha.com/news/3364670-afternoon-rally-in-cryptos?source=tweet\" data-url=\"https://seekingalpha.com/news/3364670-afternoon-rally-in-cryptos\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364667\" data-ts=\"1529345487\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364667-insys-continues-transformation-40-of-workforce-new-to-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insys continues transformation, 40% of workforce new to company</a></h4><ul><li>INSYS Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='red'>-5%</font>) <a href=\"https://seekingalpha.com/pr/17194656-insys-therapeutics-provides-update-ongoing-transformation\" target=\"_blank\">updates </a>investors on its planned transformation from its opioid marketing-tainted past. Key points:</li><li>2/3 of the board is new, all independent except for CEO Saeed Motahari.</li><li>Most managers are new, including those running sales and marketing.</li><li>More than 40% of the workforce is new, about 132 people.</li><li>Almost half of the field force is new.</li><li>NDAs for naloxone nasal spray (for opioid overdose) and epinephrine nasal spray (anaphylaxis) are on tap for 2018 and 2019, respectively.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364667\" data-linked=\"Insys continues transformation, 40% of workforce new to company\" data-tweet=\"$INSY $INSYQ - Insys continues transformation, 40% of workforce new to company https://seekingalpha.com/news/3364667-insys-continues-transformation-40-of-workforce-new-to-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3364667-insys-continues-transformation-40-of-workforce-new-to-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364668\" data-ts=\"1529345462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBX\" target=\"_blank\">DBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364668-dropbox-hits-new-all-time-high-carries-recent-tech-ipos\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dropbox hits new all-time high, carries other recent tech IPOs</a></h4><ul><li>        Dropbox (NASDAQ:<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox'>DBX</a>) shares hit a new all-time high intraday before retreating a bit.</li><li>               Newly public tech companies Zuora (<a href='https://seekingalpha.com/symbol/ZUO' title='Zuora, Inc.'>ZUO</a> <font color='green'>+7.7%</font>), Ceridian (<a href='https://seekingalpha.com/symbol/CDAY' title='Ceridian HCM Holding Inc.'>CDAY</a> <font color='green'>+8.2%</font>), and DocuSign (<a href='https://seekingalpha.com/symbol/DOCU' title='DocuSign, Inc.'>DOCU</a> <font color='green'>+2.4%</font>) are also on the move.&nbsp;</li><li>               Potential catalyst: SurveyMonkey (NASDAQ:<a href='https://seekingalpha.com/symbol/SVMK' title='SurveyMonkey'>SVMK</a>) became the latest tech company to approach an IPO. The company submitted a draft registration statement.&nbsp;&nbsp;</li><li>               Dropbox shares are&nbsp;<font color='green'>up 7%</font>&nbsp;to $42.37. Shares&nbsp;<font color='green'>gained 32%</font>&nbsp;in the past week,&nbsp;<font color='green'>28.8%</font>&nbsp;in the past month, and&nbsp;<font color='green'>39%</font>&nbsp;YTD since the IPO.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364636-surveymonkey-preps-go-public\" target=\"_blank\">SurveyMonkey preps to go public</a> (June 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364668\" data-linked=\"Dropbox hits new all-time high, carries other recent tech IPOs\" data-tweet=\"$DBX $DBX $ZUO - Dropbox hits new all-time high, carries other recent tech IPOs https://seekingalpha.com/news/3364668-dropbox-hits-new-all-time-high-carries-recent-tech-ipos?source=tweet\" data-url=\"https://seekingalpha.com/news/3364668-dropbox-hits-new-all-time-high-carries-recent-tech-ipos\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364666\" data-ts=\"1529345356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEVO\" target=\"_blank\">GEVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364666-gevo-soars-300-epa-approves-higher-blend-level-for-isobutanol\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gevo soars ~300% as EPA approves higher blend level for isobutanol</a></h4><ul>     <li>Shares of Gevo (<a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='green'>+304.3%</font>) nearly quadruple after the Environmental Protection Agency <a href=\"https://seekingalpha.com/pr/17194285-epa-approves-registration-isobutanol-16-percent-blends-gasoline\" target=\"_blank\">approves the use of isobutanol at a 16% blend level</a> in gasoline for on-road use in automobiles, up from a 12.5% blend previously.</li>     <li>Gevo praises the decision, saying 16% blend levels will allow more RINS per gallon, high octane and many other benefits.</li>     <li>The EPA approved the higher level of isobutanol after a request from Butamax Advanced Biofuels.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364666\" data-linked=\"Gevo soars ~300% as EPA approves higher blend level for isobutanol\" data-tweet=\"$GEVO - Gevo soars ~300% as EPA approves higher blend level for isobutanol https://seekingalpha.com/news/3364666-gevo-soars-300-epa-approves-higher-blend-level-for-isobutanol?source=tweet\" data-url=\"https://seekingalpha.com/news/3364666-gevo-soars-300-epa-approves-higher-blend-level-for-isobutanol\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364664\" data-ts=\"1529344882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEVO\" target=\"_blank\">GEVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364664-energy-materials-top-5-gainers-losers-of-2-00-pm-06-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/18/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='green'>+323%</font>. <a href='https://seekingalpha.com/symbol/EGC' title='Energy XXI Gulf Coast, Inc.'>EGC</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BTE' title='Baytex Energy Corp.'>BTE</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SDT' title='SandRidge Mississippian Trust I'>SDT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SDPI' title='Superior Drilling Products, Inc.'>SDPI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SHI' title='Sinopec Shanghai Petrochemical Company Limited'>SHI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AKG' title='Asanko Gold Inc.'>AKG</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364664\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/18/2018)\" data-tweet=\"$GEVO $GEVO $EGC - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/18/2018) https://seekingalpha.com/news/3364664-energy-materials-top-5-gainers-losers-of-2-00-pm-06-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364664-energy-materials-top-5-gainers-losers-of-2-00-pm-06-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364662\" data-ts=\"1529344302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPQ\" target=\"_blank\">HPQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364662-hp-launches-3d-printing-center-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HP launches 3D printing center in China</a></h4><ul><li>        HP (NYSE:<a href='https://seekingalpha.com/symbol/HPQ' title='HP Inc.'>HPQ</a>) and Guangdong 3D Printing Collaborative Innovation Platform <a href=\"https://seekingalpha.com/pr/17194078-guangdong-dali-3d-printing-collaborative-innovation-platform-hp-introduce-production-grade-3d\" target=\"_blank\">unveil</a> a new 3D printing center in China.</li><li>               The Lanwan Intelligence-HP Multi Jet Fusion Technology Mass Manufacturing Center is powered with ten HP Multi Jet Fusion 3D printing systems for functional prototypes and production-grade parts.&nbsp;</li><li>               The new endeavor marks HP&rsquo;s largest deployment of production-grade 3D printing in the Asia Pacific and Japan region.&nbsp;</li><li>                  HP shares are&nbsp;<font color='green'>up 0.5%</font>&nbsp;to $23.70. &nbsp;   </li></ul><div class=\"tiny-share-widget\" data-id=\"3364662\" data-linked=\"HP launches 3D printing center in China\" data-tweet=\"$HPQ - HP launches 3D printing center in China https://seekingalpha.com/news/3364662-hp-launches-3d-printing-center-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3364662-hp-launches-3d-printing-center-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364661\" data-ts=\"1529344204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMC\" target=\"_blank\">AMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364661-strong-debut-for-incredibles-2-boosts-exhibitors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong debut for Incredibles 2 boosts exhibitors</a></h4><ul> <li>AMC Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a>) is&nbsp;<font color='green'>up 2.40%</font>&nbsp;and IMAX (NYSE:<a href='https://seekingalpha.com/symbol/IMAX' title='IMAX Corporation'>IMAX</a>) is<font color='green'> 2.74% higher</font>&nbsp;after <em>Incredibles 2</em> blows past estimates with its opening weekend by hauling in $180M in the U.S.</li> <li>Cinemark Holdings (<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc'>CNK</a> <font color='green'>+0.9%</font>) is also beating broad market averages on the day.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364452-incredibles-2-shatters-box-office-record\" target=\"_blank\">Incredibles 2 shatters box office record</a> (June 17)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3364661\" data-linked=\"Strong debut for Incredibles 2 boosts exhibitors\" data-tweet=\"$AMC $AMC $IMAX - Strong debut for Incredibles 2 boosts exhibitors https://seekingalpha.com/news/3364661-strong-debut-for-incredibles-2-boosts-exhibitors?source=tweet\" data-url=\"https://seekingalpha.com/news/3364661-strong-debut-for-incredibles-2-boosts-exhibitors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364658\" data-ts=\"1529343401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGIO\" target=\"_blank\">AGIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364658-agios-launches-late-stage-study-of-agminus-348-in-pkd-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agios launches late-stage study of AG-348 in PKD; shares up 2%</a></h4><ul><li>Agios Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a> <font color='green'>+1.7%</font>) <a href=\"https://seekingalpha.com/pr/17193982-agios-announces-initiation-global-phase-3-trial-activate-agminus-348-adults-pyruvate-kinase\" target=\"_blank\">initiates </a>a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03548220?intr=AG-348&amp;lead=agios&amp;rank=4\" target=\"_blank\">ACTIVATE</a>, evaluating PKR enzyme activator AG-348 in 80 adults with pyruvate kinase deficiency &#40;PKD&#41; who do not receive regular blood transfusions.</li><li>The primary endpoint is the proportion of patients achieving a hemoglobin response from baseline. According to ClinicalTrials.gov, the estimated primary completion date is December 2020.</li><li>PKD is a rare inherited disorder that presents as hemolytic anemia (accelerated destruction of red blood cells).</li></ul><div class=\"tiny-share-widget\" data-id=\"3364658\" data-linked=\"Agios launches late-stage study of AG-348 in PKD; shares up 2%\" data-tweet=\"$AGIO - Agios launches late-stage study of AG-348 in PKD; shares up 2% https://seekingalpha.com/news/3364658-agios-launches-late-stage-study-of-agminus-348-in-pkd-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3364658-agios-launches-late-stage-study-of-agminus-348-in-pkd-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364647\" data-ts=\"1529342278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARWR\" target=\"_blank\">ARWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364647-arrowhead-pharma-up-24-on-advancement-of-aro-aat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arrowhead Pharma up 24% on advancement of ARO-AAT</a></h4><ul><li>Arrowhead Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='green'>+24.3%</font>) is up more than double normal volume in response to its <a href=\"https://seekingalpha.com/pr/17194050-arrowhead-completes-enrollment-phase-1-study-aro-aat-treatment-alphaminus-1-liver-disease\" target=\"_blank\">announcement </a>that it has completed enrollment in a Phase 1 clinical trial assessing RNAi therapeutic ARO-AAT in patients with alpha-1 antitrypsin deficiency.</li><li>Of particular note is the elimination of two planned cohorts at the 400 mg dose after \"maximal activity\" was observed at lower doses than expected.</li><li>Initial data will be submitted for presentation at The Liver Meeting in November.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364647\" data-linked=\"Arrowhead Pharma up 24% on advancement of ARO-AAT\" data-tweet=\"$ARWR - Arrowhead Pharma up 24% on advancement of ARO-AAT https://seekingalpha.com/news/3364647-arrowhead-pharma-up-24-on-advancement-of-aro-aat?source=tweet\" data-url=\"https://seekingalpha.com/news/3364647-arrowhead-pharma-up-24-on-advancement-of-aro-aat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364644\" data-ts=\"1529341899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENGIY\" target=\"_blank\">ENGIY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364644-engie-sees-250m-2018-hit-on-revisions-of-belgian-nuclear-units\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Engie sees \u20ac250M 2018 hit on revisions of Belgian nuclear units</a></h4><ul>     <li>Engie (<a href='https://seekingalpha.com/symbol/ENGIY' title='ENGIE SA ADR'>OTCPK:ENGIY</a> <font color='red'>-4.9%</font>) says it expects to <a href=\"https://www.nasdaq.com/article/engie-sees-shortfall-in-ebitda-on-scheduled-revisions-of-belgian-nuclear-units-20180618-00105\" target=\"_blank\">record a &euro;250M ($289M) hit to its 2018 earnings</a> after adjusting the revision program for three nuclear units.</li>     <li>Engie says the revisions represent the equivalent of more than seven additional cumulative non-operating months in 2018 for an equivalent of a second generation unit, with no impact on 2019.</li>     <li>Engie&rsquo;s Belgian unit Electrabel says it will revise the agenda of the scheduled revisions of the Tihange 2 and Doel 4 nuclear units and extend the closure of the Tihange 3 plant because of problems with deteriorating concrete.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364644\" data-linked=\"Engie sees \u20ac250M 2018 hit on revisions of Belgian nuclear units\" data-tweet=\"$ENGIY - Engie sees \u20ac250M 2018 hit on revisions of Belgian nuclear units https://seekingalpha.com/news/3364644-engie-sees-250m-2018-hit-on-revisions-of-belgian-nuclear-units?source=tweet\" data-url=\"https://seekingalpha.com/news/3364644-engie-sees-250m-2018-hit-on-revisions-of-belgian-nuclear-units\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364637\" data-ts=\"1529341418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RYTM\" target=\"_blank\">RYTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364637-rhythm-pharmas-setmelanotide-shows-positive-action-in-rare-obesity-disorders-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rhythm Pharma&#39;s setmelanotide shows positive action in rare obesity disorders; investors unmoved, shares down 9%</a></h4><ul><li>Thinly traded Rhythm Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RYTM' title='Rhythm Pharmaceuticals, Inc.'>RYTM</a> <font color='red'>-8.7%</font>) is down on below average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17194022-rhythm-pharmaceuticals-announces-new-topline-clinical-data-ongoing-phase-2-basket-studies\" target=\"_blank\">announcement </a>of new data from basket studies of MC4R receptor agonist setmelanotide in patients with rare inherited obesity disorders.</li><li>Four patients with Bardet-Biedl Syndrome &#40;BBS&#41; treated with setmelanotide experienced an average weight loss of 18.5% with an average decrease on hunger score of 74.2%.</li><li>The first patient with Alstr&ouml;m Syndrome &#40;AS&#41; experienced a 23.2% loss in weight and 45.5% decrease in hunger score.</li><li>Two patients with pro-opiomelanocortin &#40;POMC&#41; and other MC4 pathway heterozygous deficiency obesities experienced weight losses of 15.4% and 6.5%, respectively, during treatment.</li><li>A combined study in BBS and AS should launch by year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364637\" data-linked=\"Rhythm Pharma&#39;s setmelanotide shows positive action in rare obesity disorders; investors unmoved, shares down 9%\" data-tweet=\"$RYTM - Rhythm Pharma&#39;s setmelanotide shows positive action in rare obesity disorders; investors unmoved, shares down 9% https://seekingalpha.com/news/3364637-rhythm-pharmas-setmelanotide-shows-positive-action-in-rare-obesity-disorders-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3364637-rhythm-pharmas-setmelanotide-shows-positive-action-in-rare-obesity-disorders-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364640\" data-ts=\"1529341311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDLY\" target=\"_blank\">MDLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364640-financials-top-gainers-losers-of-1-00-pm-06-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top Gainers / Losers as of 1:00 PM (06/18/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management'>MDLY</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HX' title='Hexindai Inc.'>HX</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/LYL' title='Dragon Victory International Limited'>LYL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BBDO' title='Banco Bradesco S.A.'>BBDO</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BFR' title='BBVA Banco Francés S.A.  ADR'>BFR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364640\" data-linked=\"Financials - Top Gainers / Losers as of 1:00 PM (06/18/2018)\" data-tweet=\"$MDLY $MDLY $HX - Financials - Top Gainers / Losers as of 1:00 PM (06/18/2018) https://seekingalpha.com/news/3364640-financials-top-gainers-losers-of-1-00-pm-06-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364640-financials-top-gainers-losers-of-1-00-pm-06-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364638\" data-ts=\"1529340986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLR\" target=\"_blank\">CLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364638-continental-resources-hamm-pulls-out-of-opec-meeting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Continental Resources&#39; Hamm pulls out of OPEC meeting</a></h4><ul>     <li>Continental Resources (<a href='https://seekingalpha.com/symbol/CLR' title='Continental Resources, Inc.'>CLR</a> <font color='green'>+2.7%</font>) says CEO and founder Harold Hamm has <a href=\"https://www.reuters.com/article/us-oil-opec-contl-resources/continental-resources-ceo-harold-hamm-pulls-out-of-opec-meeting-idUSKBN1JE1VW\" target=\"_blank\">canceled a scheduled appearance</a> at this week's OPEC meeting in Vienna, leaving only two U.S. shale executives set to speak at the event out of an original five.</li>     <li>Hamm's withdrawal comes days after trade tensions between the U.S. and China intensified, with China imposing $50B in retaliatory tariffs on U.S. crude oil and other goods; CLR has been a key supplier of crude oil to China, shipping more than 1M barrels to the country since a U.S. crude export ban was lifted in 2015.</li>     <li>Centennial Resource Development (<a href='https://seekingalpha.com/symbol/CDEV' title='Centennial Resource Development'>CDEV</a> <font color='green'>+3.1%</font>) CEO Mark Papa and ConocoPhillips (<a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a> <font color='green'>+2.9%</font>) CEO Ryan Lance earlier withdrew from the OPEC event; Pioneer Natural Resources (<a href='https://seekingalpha.com/symbol/PXD' title='Pioneer Natural Resources Company'>PXD</a> <font color='green'>+1%</font>) Executive Chairman Scott Sheffield and Hess (<a href='https://seekingalpha.com/symbol/HES' title='Hess Corporation'>HES</a> <font color='green'>+2.4%</font>)&nbsp;CEO John Hess are still scheduled to attend.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364638\" data-linked=\"Continental Resources&#39; Hamm pulls out of OPEC meeting\" data-tweet=\"$CLR $CLR $CDEV - Continental Resources&#39; Hamm pulls out of OPEC meeting https://seekingalpha.com/news/3364638-continental-resources-hamm-pulls-out-of-opec-meeting?source=tweet\" data-url=\"https://seekingalpha.com/news/3364638-continental-resources-hamm-pulls-out-of-opec-meeting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364634\" data-ts=\"1529340547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEVO\" target=\"_blank\">GEVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364634-midday-gainers-losers-06-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (06/18/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='green'>+236%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='green'>+48%</font>. <a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CBPO' title='China Biologic Products, Inc.'>CBPO</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/EGC' title='Energy XXI Gulf Coast, Inc.'>EGC</a> <font color='green'>+19%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='red'>-58%</font>. <a href='https://seekingalpha.com/symbol/AMBO' title='Ambow Education Holding Ltd.'>AMBO</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/HX' title='Hexindai Inc.'>HX</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/EARS' title='Auris Medical Holding'>EARS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/BTE' title='Baytex Energy Corp.'>BTE</a> <font color='red'>-13%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3364634\" data-linked=\"Midday Gainers / Losers (06/18/2018)\" data-tweet=\"$GEVO $GEVO $LFIN - Midday Gainers / Losers (06/18/2018) https://seekingalpha.com/news/3364634-midday-gainers-losers-06-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364634-midday-gainers-losers-06-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364632\" data-ts=\"1529340049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTK\" target=\"_blank\">CYTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364632-cytokinetics-down-15-mid-stage-data-on-sma-drug-reldesemtiv-fails-to-excite-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cytokinetics down 15% as mid-stage data on SMA drug reldesemtiv fails to excite investors</a></h4><ul><li>Thinly traded Cytokinetics (<a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color='red'>-15.2%</font>) slumps on almost triple normal volume, albeit on turnover of only 835K shares, in response to its <a href=\"https://seekingalpha.com/pr/17193826-cytokinetics-announces-data-phase-2-clinical-study-reldesemtiv-patients-spinal-muscular\" target=\"_blank\">announcement </a>of Phase 2 proof-of-concept data on reldesemtiv in patients with spinal muscular atrophy &#40;SMA&#41;. The results were presented at the Annual Cure SMA Conference in Dallas, TX.</li><li>SMA patients receiving 150 mg of reldesemtiv showed a 10.86-meter increase in six-minute walk distance (6MWD) versus placebo after four weeks of treatment, although this moderated to 7.72 meters after eight weeks of treatment. Patients receiving 450 mg experienced an increase of 35.63 meters versus placebo at week 4, but eased to 24.89 meters at week 8. The 450 mg/4 week result was the only one that was statistically significant.</li><li>Other metrics also showed statistically valid correlations with particular doses of the drug compared to placebo.</li><li>Reldesemtiv is a next-generation fast skeletal troponin activator.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364632\" data-linked=\"Cytokinetics down 15% as mid-stage data on SMA drug reldesemtiv fails to excite investors\" data-tweet=\"$CYTK - Cytokinetics down 15% as mid-stage data on SMA drug reldesemtiv fails to excite investors https://seekingalpha.com/news/3364632-cytokinetics-down-15-mid-stage-data-on-sma-drug-reldesemtiv-fails-to-excite-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3364632-cytokinetics-down-15-mid-stage-data-on-sma-drug-reldesemtiv-fails-to-excite-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364630\" data-ts=\"1529339916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GMGI\" target=\"_blank\">GMGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364630-golden-matrix-group-slides-10-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golden Matrix Group slides 10% post Q3 results</a></h4><ul><li>Golden Matrix Group (<a href='https://seekingalpha.com/symbol/GMGI' title='Golden Matrix Group, Inc.'>OTCPK:GMGI</a> <font color='red'>-10%</font>)&nbsp;<a href=\"https://seekingalpha.com/pr/17194415-golden-matrix-reports-third-quarter-2018-sales-345148-vs-30000-q3-2017\" target=\"_blank\">reports Q3</a> revenue growth of 1066.7% Y/Y to $0.35M, the jump in revenue was primarily a result of only two months of activities from the newly acquired technology.</li><li>The loss reported in Q3 was adversely impacted by two noncash charges related to the acquisition of proprietary gaming technology by the company - along with a licensing and distribution agreement to monetize its deployment. These charges were an amortization expense of $0.07M and G&amp;A related-party expenses of $0.3M for stock issued to acquire the proprietary technology.</li><li>The company entered into an Asset Purchase Agreement to acquire the unique gaming technology, along with certain intellectual property and know-how, from Luxor Capital LLC.</li><li>Also, entered into a definitive license and distribution agreement with Articulate.</li><li>Subscription agreement with certain individual investors was carried out in which the Company sold 0.3B shares of restricted common stock, and received non-brokered gross proceeds of $0.12M.</li><li>&ldquo;We are confident that the current and future quarters will be generating solid, recurring monthly sales and positive cash flow, and we expect our ongoing marketing efforts to add more social gaming operators and contribute to profitable operating results.&rdquo; said Anthony Goodman, CEO.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364542-golden-matrix-group-reports-q3-results\" target=\"_blank\">Golden Matrix Group reports Q3 results</a> (June 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364630\" data-linked=\"Golden Matrix Group slides 10% post Q3 results\" data-tweet=\"$GMGI - Golden Matrix Group slides 10% post Q3 results https://seekingalpha.com/news/3364630-golden-matrix-group-slides-10-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3364630-golden-matrix-group-slides-10-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364626\" data-ts=\"1529339095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SATS\" target=\"_blank\">SATS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364626-inmarsatplus-2_6-on-report-echostar-weighs-boosting-takeout-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inmarsat +2.6% on report EchoStar weighs boosting takeout offer</a></h4><ul>   <li>After getting spurned with a previous bid, EchoStar (NASDAQ:<a href='https://seekingalpha.com/symbol/SATS' title='EchoStar Corporation'>SATS</a>) is <a href=\"https://www.bloomberg.com/news/articles/2018-06-18/echostar-is-said-to-weigh-raising-inmarsat-bid-after-rejection\" target=\"_blank\">looking at raising an offer to buy</a> rival Inmarsat (<a href='https://seekingalpha.com/symbol/IMASY' title='Inmarsat Plc. ADR'>OTCPK:IMASY</a>), Bloomberg reports.</li>    <li><a href='https://seekingalpha.com/symbol/IMASY' title='Inmarsat Plc. ADR'>OTCPK:IMASY</a> is <font color='green'>up 2.6%</font>; <a href='https://seekingalpha.com/symbol/SATS' title='EchoStar Corporation'>SATS</a> <font color='red'>down 0.8%</font>.</li>    <li>The firm is talking with financial advisers and discussing financing to boost its bid, though a final decision hasn't been made, according to the report.</li>    <li>Inmarsat had <a href=\"https://seekingalpha.com/news/3362793-inmarsat-rejects-takeover-approach-echostar\" target=\"_blank\">rejected a previous bid</a> 10 days ago.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364626\" data-linked=\"Inmarsat +2.6% on report EchoStar weighs boosting takeout offer\" data-tweet=\"$SATS $SATS $IMASY - Inmarsat +2.6% on report EchoStar weighs boosting takeout offer https://seekingalpha.com/news/3364626-inmarsatplus-2_6-on-report-echostar-weighs-boosting-takeout-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3364626-inmarsatplus-2_6-on-report-echostar-weighs-boosting-takeout-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364624\" data-ts=\"1529338460\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364624-dryships-pulls-out-of-gas-ships-spinoff-sells-two-panamaxes-for-18_8m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips pulls out of Gas Ships spinoff, sells two Panamaxes for $18.8M</a></h4><ul>     <li>DryShips (<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+3.3%</font>) is higher after saying it <a href=\"https://splash247.com/dryships-backs-gas-ships-spin-off/\" target=\"_blank\">will not proceed with plans to spin off</a> its Gas Ships gas carrier business, and has withdrawn the F-1 statement with the SEC.</li>     <li>DRYS announced the spinoff plan in February, in which it would have retained a 51% stake in the business with shareholders taking a 49% stake in the newly public company.</li>     <li>DRYS also <a href=\"https://seekingalpha.com/pr/17193659-dryships-inc-announces-agreements-sell-two-older-panamaxes\" target=\"_blank\">agrees to sell</a> two of its older  Panamax drybulk carriers to unspecified buyers for a combined $18.8M.</li>     <li>The company continues to operate a fleet of 36 vessels, including 11 Panamax drybulk vessels.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364624\" data-linked=\"DryShips pulls out of Gas Ships spinoff, sells two Panamaxes for $18.8M\" data-tweet=\"$DRYS - DryShips pulls out of Gas Ships spinoff, sells two Panamaxes for $18.8M https://seekingalpha.com/news/3364624-dryships-pulls-out-of-gas-ships-spinoff-sells-two-panamaxes-for-18_8m?source=tweet\" data-url=\"https://seekingalpha.com/news/3364624-dryships-pulls-out-of-gas-ships-spinoff-sells-two-panamaxes-for-18_8m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364622\" data-ts=\"1529338246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSDT\" target=\"_blank\">HSDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364622-helios-to-file-u-s-marketing-application-for-pons-device-in-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helios to file U.S. marketing application for PoNS device in Q3</a></h4><ul><li>Thinly traded micro cap Helius Medical Technologies (<a href='https://seekingalpha.com/symbol/HSDT' title='Helius Medical Technologies, Inc.'>HSDT</a> <font color='red'>-2.8%</font>) <a href=\"https://seekingalpha.com/pr/17194027-helius-medical-technologies-inc-provides-update-anticipated-submission-fda-clearance-pons\" target=\"_blank\">announces</a> that it expects to file a marketing application with the FDA next quarter seeking 510(k) clearance under de novo status for its Portable Neuromodulation Stimulator (PoNS).</li><li>The device enables tongue-delivered neuromodulation, combined with cranial nerve stimulation and physical and cognitive therapy, to restore lost neurological function.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364622\" data-linked=\"Helios to file U.S. marketing application for PoNS device in Q3\" data-tweet=\"$HSDT - Helios to file U.S. marketing application for PoNS device in Q3 https://seekingalpha.com/news/3364622-helios-to-file-u-s-marketing-application-for-pons-device-in-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3364622-helios-to-file-u-s-marketing-application-for-pons-device-in-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364619\" data-ts=\"1529337632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAKD\" target=\"_blank\">NAKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364619-consumer-top-gainers-losers-of-12-00-pm-06-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (06/18/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi Inc.'>FAMI</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CRESY' title='Cresud S.A.C.I.F. y A.'>CRESY</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364619\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (06/18/2018)\" data-tweet=\"$NAKD $NAKD $VNCE - Consumer - Top Gainers / Losers as of 12:00 PM (06/18/2018) https://seekingalpha.com/news/3364619-consumer-top-gainers-losers-of-12-00-pm-06-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364619-consumer-top-gainers-losers-of-12-00-pm-06-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364615\" data-ts=\"1529336419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGN\" target=\"_blank\">IMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364615-immunogens-mirvetuximab-soravtansine-fast-trackd-for-treatment-resistant-ovarian-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmunoGen&#39;s mirvetuximab soravtansine Fast Track&#39;d for treatment-resistant ovarian cancer; shares up 5%</a></h4><ul><li>ImmunoGen (<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+4.9%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17194138-immunogen-announces-fda-fast-track-designation-mirvetuximab-soravtansine-patients-platinum\" target=\"_blank\">announcement </a>that the FDA has granted Fast Track status for antibody-drug conjugate mirvetuximab soravtansine for the treatment of patients with medium-to-high folate receptor alpha-positive platinum-resistant ovarian cancer who have received at least one, but no more than three, prior lines of systemic therapy and for whom single-agent chemo is appropriate as the next line of treatment.</li><li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li><li>Topline data from the Phase 3 FORWARD I study should be available in H1 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364615\" data-linked=\"ImmunoGen&#39;s mirvetuximab soravtansine Fast Track&#39;d for treatment-resistant ovarian cancer; shares up 5%\" data-tweet=\"$IMGN - ImmunoGen&#39;s mirvetuximab soravtansine Fast Track&#39;d for treatment-resistant ovarian cancer; shares up 5% https://seekingalpha.com/news/3364615-immunogens-mirvetuximab-soravtansine-fast-trackd-for-treatment-resistant-ovarian-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3364615-immunogens-mirvetuximab-soravtansine-fast-trackd-for-treatment-resistant-ovarian-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364606\" data-ts=\"1529335931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYA\" target=\"_blank\">PBYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364606-probility-media-jumps-26-on-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Probility Media jumps 26% on Q2 results</a></h4><ul><li>ProBility Media (<a href='https://seekingalpha.com/symbol/PBYA' title='Probility Media Corp.'>OTCQB:PBYA</a> <font color='green'>+26.2%</font>)&nbsp;reported Q2 revenue growth of 118% Y/Y to $4.02M, increase was due to sales from acquired companies that realized a total of $2.16M in sales.</li><li>Q2 Gross margin&nbsp;<font color='green'>improved by 357 bps</font>&nbsp;to 41.1% as the company shifted product focus from printed materials to higher margin training and eLearning products.</li><li>Total operating expenses were $2.89M (+119.2% Y/Y) due to increase in cost of sales from acquisitions.</li><li>Q2 Net loss was $4.36M compared to $0.51M in prior year, reflecting the impact by the change in the derivative liability, a noncash expense, and higher interest expense due to higher note balances.</li><li>Disco Learning Media secured a contract with the&nbsp;State of Texas&nbsp;for the development of a series of new STEM programs and also renewed contract with the Minnesota Historical Society.</li><li>&ldquo;As we continue to execute on our growth strategy we believe we have the opportunity to explore more advantageous forms of financing with the intention of a more positive impact on our balance sheet. We believe that our second-quarter results validate both our growth strategy, and the ongoing acceptance of ProBility as a leading provider of educational and training materials within the industrial trades&rdquo;, mentioned Evan Levine, CEO.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364535-probility-media-reports-q2-results\" target=\"_blank\">Probility Media reports Q2 results</a> (June 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364606\" data-linked=\"Probility Media jumps 26% on Q2 results\" data-tweet=\"$PBYA - Probility Media jumps 26% on Q2 results https://seekingalpha.com/news/3364606-probility-media-jumps-26-on-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3364606-probility-media-jumps-26-on-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364610\" data-ts=\"1529335422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYGN\" target=\"_blank\">MYGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364610-fda-accepts-myriad-genetics-application-for-bracanalysis-cdx-companion-diagnostic-pfizers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Myriad Genetics&#39; application for BRACAnalysis CDx as companion diagnostic with Pfizer&#39;s talazoparib, action date December; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17194031-myriad-s-bracanalysis-cdx-supplementary-pma-accepted-fda-review-companion-diagnostic\" target=\"_blank\">accepts </a>under Priority Review Myriad Genetics' (<a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a> <font color='green'>+0.8%</font>) marketing application seeking approval to use its BRACAnalysis CDx test as a companion diagnostic with Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='red'>-1.3%</font>) PARP inhibitor talazoparib. The agency's action date is in December.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364610\" data-linked=\"FDA accepts Myriad Genetics&#39; application for BRACAnalysis CDx as companion diagnostic with Pfizer&#39;s talazoparib, action date December; shares up 1%\" data-tweet=\"$MYGN $MYGN $PFE - FDA accepts Myriad Genetics&#39; application for BRACAnalysis CDx as companion diagnostic with Pfizer&#39;s talazoparib, action date December; shares up 1% https://seekingalpha.com/news/3364610-fda-accepts-myriad-genetics-application-for-bracanalysis-cdx-companion-diagnostic-pfizers?source=tweet\" data-url=\"https://seekingalpha.com/news/3364610-fda-accepts-myriad-genetics-application-for-bracanalysis-cdx-companion-diagnostic-pfizers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364607\" data-ts=\"1529335219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOK\" target=\"_blank\">NOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364607-nokiaminus-1_8-in-u-s-trade-santander-cuts-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nokia -1.8% in U.S. trade as Santander cuts to Underweight</a></h4><ul>   <li>Shares of Nokia (NYSE:<a href='https://seekingalpha.com/symbol/NOK' title='Nokia Corporation'>NOK</a>) are <font color='red'>1.8% lower</font> in NYSE trading today after a downgrade to Underweight at Santander.</li>    <li>The bank updated its price target higher, to &euro;5.40; that's about 4.7% upside from today's close in Helsinki of &euro;5.16.</li>    <li>It's one of just a few Sell-level ratings against more than a dozen Buys, though.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364607\" data-linked=\"Nokia -1.8% in U.S. trade as Santander cuts to Underweight\" data-tweet=\"$NOK - Nokia -1.8% in U.S. trade as Santander cuts to Underweight https://seekingalpha.com/news/3364607-nokiaminus-1_8-in-u-s-trade-santander-cuts-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3364607-nokiaminus-1_8-in-u-s-trade-santander-cuts-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364599\" data-ts=\"1529334034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBSV\" target=\"_blank\">OBSV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364599-healthcare-top-5-gainers-losers-of-11-00-06-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/18/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/CBPO' title='China Biologic Products, Inc.'>CBPO</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='green'>+18%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='red'>-56%</font>. <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/NSPR' title='InspireMD, Inc.'>NSPR</a> <font color='red'>-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364599\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/18/2018)\" data-tweet=\"$OBSV $OBSV $CBPO - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/18/2018) https://seekingalpha.com/news/3364599-healthcare-top-5-gainers-losers-of-11-00-06-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364599-healthcare-top-5-gainers-losers-of-11-00-06-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364597\" data-ts=\"1529333900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364597-disneyminus-1_5-pivotal-goes-to-sell-amid-fox-deal-bumps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney -1.5% as Pivotal goes to Sell amid Fox-deal bumps</a></h4><ul>   <li>Disney's (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) <font color='red'>off 1.5%</font> following a morning downgrade to Sell from Pivotal Research, and amid news that the company is looking to add cash to its Fox media-asset bid to ward off an all-cash offer from Comcast.</li>    <li>Pivotal's Brian Wieser notes the damned-if-you do, damned-if-you-don't nature of the Fox fight: Paying more for the Fox assets would definitely \"reduce the value of Disney to its shareholders\"; meanwhile, without the deal its strategic position is weaker without expected synergies.</li>    <li>Disney can still emphasize a direct-to-consumer approach without the Fox assets, but its propositions both to viewers and to content creators is stronger with Fox. (h/t Bloomberg)</li>    <li>Wieser's price target is at $93, vs. Disney's current price of $107.25 (13.3% downside).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364597\" data-linked=\"Disney -1.5% as Pivotal goes to Sell amid Fox-deal bumps\" data-tweet=\"$DIS - Disney -1.5% as Pivotal goes to Sell amid Fox-deal bumps https://seekingalpha.com/news/3364597-disneyminus-1_5-pivotal-goes-to-sell-amid-fox-deal-bumps?source=tweet\" data-url=\"https://seekingalpha.com/news/3364597-disneyminus-1_5-pivotal-goes-to-sell-amid-fox-deal-bumps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364595\" data-ts=\"1529333758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBO\" target=\"_blank\">AMBO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364595-ambow-education-peels-off-19-in-share-price\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ambow Education peels off 19% in share price</a></h4><ul> <li>Ambow Education (NYSEMKT:<a href='https://seekingalpha.com/symbol/AMBO' title='Ambow Education Holding Ltd.'>AMBO</a>) is <font color='red'>down 19.2%</font> to $5.94 as the education stock cools off a bit from last week's rocket ride.</li> <li>The company hasn't posted any news or SEC filings to account for the shift in sentiment.</li> <li>Ambow priced its public offering of shares at $4.25 per ADS on June 1.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3364595\" data-linked=\"Ambow Education peels off 19% in share price\" data-tweet=\"$AMBO - Ambow Education peels off 19% in share price https://seekingalpha.com/news/3364595-ambow-education-peels-off-19-in-share-price?source=tweet\" data-url=\"https://seekingalpha.com/news/3364595-ambow-education-peels-off-19-in-share-price\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364592\" data-ts=\"1529332957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364592-microsoft-acquires-video-sharing-platform-for-education\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft acquires video sharing platform for education</a></h4><ul><li>        Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) <a href=\"https://venturebeat.com/2018/06/18/this-nvidia-neural-network-can-apply-slow-motion-to-any-video/\" target=\"_blank\">announces</a>&nbsp;acquiring Flipgrid, a video sharing platform for students and educators, for an undisclosed amount.</li><li>               Microsoft will make Flipgrid free for schools compared to the previous subscription plans of $40/year for educators, $800/year for school districts, and $1,000/year for schools. Customers who already paid for a subscription will receive a prorated refund.&nbsp;</li><li>                  Flipgrid has more than 20M teachers and students in 180 countries using the platform.    </li><li>               The acquisition helps Microsoft move deeper into the educational market dominated by Google. In the US, nearly 60% of mobile personal computing devices shipped to schools in Q4 were Chromebooks, according to Futuresource data, and less than 26% ran Windows.&nbsp;</li><li>               Microsoft shares are<font color='green'> up 0.7%</font>&nbsp;to $100.78.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3364592\" data-linked=\"Microsoft acquires video sharing platform for education\" data-tweet=\"$MSFT - Microsoft acquires video sharing platform for education https://seekingalpha.com/news/3364592-microsoft-acquires-video-sharing-platform-for-education?source=tweet\" data-url=\"https://seekingalpha.com/news/3364592-microsoft-acquires-video-sharing-platform-for-education\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364584\" data-ts=\"1529332677\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSG\" target=\"_blank\">TSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364584-stars-groupminus-6-after-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Stars Group -6% after share offering</a></h4><ul> <li>The Stars Group (NASDAQ:<a href='https://seekingalpha.com/symbol/TSG' title='The Stars Group Inc.'>TSG</a>) is <font color='red'>down 6.34%</font> after announcing a share offering earlier today.</li> <li>The company is using the funds to pay for the acquisition of Sky Betting &amp; Gaming. If the Sky deal doesn't make it to the finish line, the company will use the funds for general corporate purposes.</li> <li>Shares of TSG are still up 53% YTD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3364584\" data-linked=\"The Stars Group -6% after share offering\" data-tweet=\"$TSG - The Stars Group -6% after share offering https://seekingalpha.com/news/3364584-stars-groupminus-6-after-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3364584-stars-groupminus-6-after-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364583\" data-ts=\"1529332369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/Z\" target=\"_blank\">Z</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364583-zillowminus-3_5-goldman-cools-on-online-real-estate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zillow -3.5% as Goldman cools on online real estate</a></h4><ul>   <li>Zillow Group (NASDAQ:<a href='https://seekingalpha.com/symbol/Z' title='Zillow Group, Inc.'>Z</a>) is <font color='red'>3.5% lower</font> after a cut to Neutral at Goldman Sachs.</li>    <li>Analyst Heath Terry is expecting seasonal underperformance in the sector, and Zillow has already \"significantly\" outperformed year-to-date (it's <font color='green'>up 60.2%</font> in that time frame). Housing and mortgage availability should continue to be tight as well.</li>    <li>Terry has a price target of $60, implying 5.1% downside from today's lower price. The firm <a href=\"https://seekingalpha.com/news/3364512-redfin-minus-4_7-percent-goldman-moves-sell\" target=\"_blank\">downgraded Redfin to Sell</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364583\" data-linked=\"Zillow -3.5% as Goldman cools on online real estate\" data-tweet=\"$Z - Zillow -3.5% as Goldman cools on online real estate https://seekingalpha.com/news/3364583-zillowminus-3_5-goldman-cools-on-online-real-estate?source=tweet\" data-url=\"https://seekingalpha.com/news/3364583-zillowminus-3_5-goldman-cools-on-online-real-estate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364581\" data-ts=\"1529332054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PPC\" target=\"_blank\">PPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364581-near-term-challenges-for-pilgrims-pride-and-sanderson-farms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Near-term challenges for Pilgrim&#39;s Pride and Sanderson Farms</a></h4><ul> <li>Stephens warns on some <a href=\"https://www.stephens.com/institutional-equities-and-research/research/featured-reports?d=20180618\" target=\"_blank\">near-term challenges</a> on Pilgrim's Pride (<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a> <font color='red'>-5.6%</font>) in a new research report, while keeping a positive view on the long-term potential for the poultry stock.</li> <li>The investment firm has PPC rated at Overweight with a price target of $26 (30% upside potential).</li>  <li>Pilgrim's Pride and Sanderson Farms (<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a> <font color='red'>-1.1%</font>) are both lower today on tariff anxiety.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3364581\" data-linked=\"Near-term challenges for Pilgrim&#39;s Pride and Sanderson Farms\" data-tweet=\"$PPC $PPC $SAFM - Near-term challenges for Pilgrim&#39;s Pride and Sanderson Farms https://seekingalpha.com/news/3364581-near-term-challenges-for-pilgrims-pride-and-sanderson-farms?source=tweet\" data-url=\"https://seekingalpha.com/news/3364581-near-term-challenges-for-pilgrims-pride-and-sanderson-farms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364576\" data-ts=\"1529331679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBXNF\" target=\"_blank\">IBXNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364576-ibex-technologies-slides-22_1-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ibex Technologies slides 22.1% post Q3 results</a></h4><ul><li>Ibex Technologies (<a href='https://seekingalpha.com/symbol/IBXNF' title='Ibex Technologies Inc.'>OTC:IBXNF</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/17194084-ibex-reports-results-third-quarter-nine-months-ended-april-30-2018\" target=\"_blank\">reports Q3</a> revenue growth of 27.3% Y/Y to C$1.4M, the increase in revenues represents a resumption of purchases by one of major customers who had excess inventory in the Q1 &amp; Q2 2018.</li><li>As a consequence of the increase in revenues, offset by an increase in expenses, the company recorded EBITDA of $0.3M (+275% Y/Y).</li><li>There were no capital expenditures for Q3 as compared year ago, the year-ago expenditures trace to the construction of the new&nbsp;Montr&eacute;al&nbsp;fermentation facility.</li><li>Cash &amp; equivalents was C$2.7M (-10.1% Y/Y); Net working capital of C$3.5M (-4.1% Y/Y) &amp; Net earnings C$0.2M</li><li>The Company continues to work on a number of projects with its key customers, some of which may result in additional revenues in 2019 and beyond; however, as with all developmental projects, there is no assurance that any of these projects will come to fruition and produce revenues.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364506-ibex-technologies-reports-9m-results\" target=\"_blank\">Ibex Technologies reports 9M results</a> (June 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364576\" data-linked=\"Ibex Technologies slides 22.1% post Q3 results\" data-tweet=\"$IBXNF - Ibex Technologies slides 22.1% post Q3 results https://seekingalpha.com/news/3364576-ibex-technologies-slides-22_1-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3364576-ibex-technologies-slides-22_1-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364577\" data-ts=\"1529331669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/T\" target=\"_blank\">T</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364577-t-launches-new-generation-of-directv-for-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AT&amp;T launches new generation of DirecTV for Business</a></h4><ul>   <li>AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color='red'>-1.8%</font>) has taken advantage of the HITEC Houston hospitality-tech show to roll out the <a href=\"https://seekingalpha.com/pr/17194460-t-launches-next-gen-video-platform-directv-business-customers\" target=\"_blank\">third iteration</a> of its DirecTV for Business platform.</li>    <li>The COM3000 video headend now offers up to 138 HD channels, including 4K programming, and allows business owners to add channels one at a time, including in-house and OTT channels.</li>    <li>It also allows for easier software upgrades to save hardware costs (while hotels will likely be the biggest beneficiary, it's optimal for any business with a lot of TVs that doesn't want a receiver at each set) and adds flexibility for guests viewing content on various devices through a number of different wiring schemes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364577\" data-linked=\"AT&amp;T launches new generation of DirecTV for Business\" data-tweet=\"$T - AT&amp;T launches new generation of DirecTV for Business https://seekingalpha.com/news/3364577-t-launches-new-generation-of-directv-for-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3364577-t-launches-new-generation-of-directv-for-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364574\" data-ts=\"1529331449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOS\" target=\"_blank\">GOOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364574-canada-goose-rockets-higher-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canada Goose rockets higher again</a></h4><ul> <li>Shares of Canada Goose (NYSE:<a href='https://seekingalpha.com/symbol/GOOS' title='Canada Goose Holdings'>GOOS</a>) are <font color='green'>up 7.68%</font> in morning trading in New York after CIBC hikes its price target on the retailer to C$92 from C$48.</li> <li>The analyst team cites the potential for Canada Goose to continue to see sales growth momentum in the direct-to-consumer channel.</li> <li>Canada Goose is <font color='green'>up 9.32%</font> in Toronto trading to $85.28.</li> <li>Canada Goose has been one of the hottest stocks in the entire retail sector, more than doubling in share price this year in the U.S. and Canada.</li> <li>Sources: MarketWatch, Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364574\" data-linked=\"Canada Goose rockets higher again\" data-tweet=\"$GOOS - Canada Goose rockets higher again https://seekingalpha.com/news/3364574-canada-goose-rockets-higher-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3364574-canada-goose-rockets-higher-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364557\" data-ts=\"1529330189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364557-tg-therapeutics-slips-2-on-mid-stage-umbralisib-data-in-treatment-resistant-cll\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics slips 2% on mid-stage umbralisib data in treatment-resistant CLL</a></h4><ul><li>TG Therapeutics (<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a> <font color='red'>-1.5%</font>) is down on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17194036-tg-therapeutics-inc-presents-phase-2-data-evaluating-umbralisib-cll-patients-intolerant-prior\" target=\"_blank\">announcement </a>of preliminary data from a Phase 2 clinical trial assessing PI3K inhibitor umbralisib (TGR-1202) in patients with relapsed/refractory chronic lymphocytic leukemia &#40;CLL&#41; who were intolerant to prior BTK or PI3K therapy (up to 40% of patients according to CEO Michael Weiss). The data were presented at EHA in Stockholm.</li><li>13% of patients receiving umbralisib discontinued treatment due to an adverse event, including one also experienced an adverse event with prior kinase inhibitor therapy.</li><li>Median progression-free survival &#40;PFS&#41; and overall survival &#40;OS&#41; had not been reached (median follow-up: 9.5 months).</li><li>\"Significant clinical activity\" was observed in this group of which 77% required treatment with six months of discontinuation of prior kinase inhibitor therapy, 64% had a high-risk molecular or genetic biomarker and 6% had a resistance mutation to AbbVie's Imbruvica (ibrutinib).</li><li>Topline data from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02612311?titles=unity-cll&amp;lead=tg+therapeutics&amp;phase=2&amp;rank=1\" target=\"_blank\">UNITY-CLL</a> study assessing the combination of umbralisib and ublituximab (TG-1101) compared to Roche's Gazyva (obinutuzumab) + chlorambucil in treatment-naive and treatment-experienced CLL patients should be available in the September time frame.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364524-verastems-duvelisib-shows-significant-treatment-effect-cll-study-shares-14-percent-premarket\" target=\"_blank\">Verastem's duvelisib shows significant treatment effect in CLL study; shares up 14% premarket</a> (June 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364557\" data-linked=\"TG Therapeutics slips 2% on mid-stage umbralisib data in treatment-resistant CLL\" data-tweet=\"$TGTX - TG Therapeutics slips 2% on mid-stage umbralisib data in treatment-resistant CLL https://seekingalpha.com/news/3364557-tg-therapeutics-slips-2-on-mid-stage-umbralisib-data-in-treatment-resistant-cll?source=tweet\" data-url=\"https://seekingalpha.com/news/3364557-tg-therapeutics-slips-2-on-mid-stage-umbralisib-data-in-treatment-resistant-cll\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364555\" data-ts=\"1529329861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364555-ubs-raises-nvidia-target-on-facial-recognition-boom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS raises its Nvidia target on facial recognition boom</a></h4><ul><li>           UBS <a href=\"https://www.cnbc.com/2018/06/18/mass-facial-recognition-boom-led-by-the-chinese-government-will-mean-big-money-for-nvidia-ubs-says.html\" target=\"_blank\">raises</a> its Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) price target from $266 to $285. </li><li> Analyst Timothy Arcuri cites a China-led facial recognition boom that could provide an additional $5B sales opportunity for Nvidia by 2020. </li><li> Nvidia&rsquo;s Metropolis platform helps governments use its AI tech to analyze video feeds with potential applications in traffic monitoring, public safety, and law enforcement. </li><li> Arcuri estimates that Nvidia currently has a nearly 90% share of the current AI chip market. </li><li> Rating reiterated at Neutral due to the stock&rsquo;s current valuation. </li><li> Nvidia shares are&nbsp;<font color='red'>down 0.8%</font>&nbsp;to $263.16.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3364555\" data-linked=\"UBS raises its Nvidia target on facial recognition boom\" data-tweet=\"$NVDA - UBS raises its Nvidia target on facial recognition boom https://seekingalpha.com/news/3364555-ubs-raises-nvidia-target-on-facial-recognition-boom?source=tweet\" data-url=\"https://seekingalpha.com/news/3364555-ubs-raises-nvidia-target-on-facial-recognition-boom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364552\" data-ts=\"1529329225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSNNF\" target=\"_blank\">SSNNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364552-semi-equipment-stocks-move-on-stifel-memory-push-out-note\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semi equipment stocks move on Stifel memory push-out note</a></h4><ul><li>        Stifel is out with a note attributing memory push-outs to Samsung (<a href='https://seekingalpha.com/symbol/SSNNF' title='Samsung Electronics Co., Ltd.'>OTC:SSNNF</a>, <a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>), primarily on the 3D NAND front. The firm lowers its 2018 WFE forecast, but is still tracking toward a record year and has raised the 2019 WFE estimates.</li><li>               Stifel thinks overall supply/demand trends remain healthy and notes that large-cap companies like Applied Materials (<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a> <font color='red'>-1.5%</font>), KLA-Tencor (<a href='https://seekingalpha.com/symbol/KLAC' title='KLA-Tencor Corporation'>KLAC</a> <font color='red'>-1.9%</font>), and Lam Research (<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color='red'>-2.2%</font>) have seen improvements in business models and cash flow generation.&nbsp;</li><li>               The firm also sees small cap companies benefitting through the ups and downs of the spending environment with MKS Instruments (<a href='https://seekingalpha.com/symbol/MKSI' title='MKS Instruments, Inc.'>MKSI</a> <font color='red'>-1.8%</font>), Advanced Energy (<a href='https://seekingalpha.com/symbol/AEIS' title='Advanced Energy Industries, Inc.'>AEIS</a> <font color='red'>-1.5%</font>), Ichor Holdings (<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a> <font color='red'>-1.7%</font>), and Ultra Clean (<a href='https://seekingalpha.com/symbol/UCTT' title='Ultra Clean Holdings, Inc.'>UCTT</a> <font color='red'>-0.2%</font>) poised to deliver healthy profits even with a quarter or two of revenue declines.&nbsp;</li><li>               Price target adjustments: MKS Instruments from $147 to $155, Ichor Holdings from $44 to $48, and Ultra Clean from $27 to $30.&nbsp;&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>                  Other semiconductor equipment stocks that could move on the note: Applied Materials (<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a> <font color='red'>-1.5%</font>), &nbsp;ASML (<a href='https://seekingalpha.com/symbol/ASML' title='ASML Holding N.V.'>ASML</a> <font color='red'>-2.6%</font>), Brooks Automation (<a href='https://seekingalpha.com/symbol/BRKS' title='Brooks Automation, Inc.'>BRKS</a> <font color='red'>-5.8%</font>), AXT (<a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a>), Nanometrics (<a href='https://seekingalpha.com/symbol/NANO' title='Nanometrics Incorporated'>NANO</a> <font color='red'>-2.5%</font>), Nova Measuring Instruments (<a href='https://seekingalpha.com/symbol/NVMI' title='Nova Measuring Instruments Ltd.'>NVMI</a> <font color='red'>-1.6%</font>), Axcelis Technologies (<a href='https://seekingalpha.com/symbol/ACLS' title='Axcelis Technologies, Inc.'>ACLS</a> <font color='red'>-0.5%</font>), Ambarella (<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a> <font color='red'>-1.2%</font>), Universal Display (<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color='red'>-2.1%</font>), Synopsys (<a href='https://seekingalpha.com/symbol/SNPS' title='Synopsys, Inc.'>SNPS</a> <font color='red'>-1.4%</font>), and Teradyne (<a href='https://seekingalpha.com/symbol/TER' title='Teradyne Inc.'>TER</a> <font color='red'>-1.5%</font>). </li></ul><div class=\"tiny-share-widget\" data-id=\"3364552\" data-linked=\"Semi equipment stocks move on Stifel memory push-out note\" data-tweet=\"$SSNNF $SSNNF $SSNLF - Semi equipment stocks move on Stifel memory push-out note https://seekingalpha.com/news/3364552-semi-equipment-stocks-move-on-stifel-memory-push-out-note?source=tweet\" data-url=\"https://seekingalpha.com/news/3364552-semi-equipment-stocks-move-on-stifel-memory-push-out-note\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364546\" data-ts=\"1529328486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364546-premarket-gainers-of-9-05-06-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (06/18/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+33%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3364527-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li><li><a href='https://seekingalpha.com/symbol/CBPO' title='China Biologic Products, Inc.'>CBPO</a> <font color='green'>+31%</font>&nbsp;on $110/share <a href=\"https://seekingalpha.com/news/3364485-china-biologic-products-16-percent-premarket-110-share-offer\" target=\"_blank\">offer</a>.</li><li><a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='green'>+31%</font>&nbsp;as EPA&nbsp;<a href=\"https://seekingalpha.com/pr/17194285-epa-approves-registration-isobutanol-16-percent-blends-gasoline\" target=\"_blank\">approves</a> registration of Isobutanol.</li><li><a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a> <font color='green'>+22%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3364511-vintage-capital-acquires-rent-center\" target=\"_blank\">acquired</a> by Vintage Capital.</li><li><a href='https://seekingalpha.com/symbol/EGC' title='Energy XXI Gulf Coast, Inc.'>EGC</a> <font color='green'>+20%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3364514-energy-xxi-gulf-coast-bought-cox-oil-9_10-share\" target=\"_blank\">acquired</a> by&nbsp;Cox Oil for $9.10/share.</li><li><a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3364496-quotient-reports-concordance-data-mosaiq-european-field-trial\" target=\"_blank\">data</a> from the MosaiQ&nbsp;European field trial.</li><li><a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3364524-verastems-duvelisib-shows-significant-treatment-effect-cll-study-shares-14-percent-premarket\" target=\"_blank\">significant</a> treatment effect in CLL study.</li><li><a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences, Inc.'>SLDB</a> <font color='green'>+14%</font>&nbsp;as FDA has&nbsp;<a href=\"https://seekingalpha.com/news/3364480-solid-biosciences-halted-pending-news\" target=\"_blank\">removed&nbsp;</a>the clinical hold on its Phase 1/2 clinical trial assessing SGT-001.</li><li><a href='https://seekingalpha.com/symbol/NMM' title='Navios Maritime Partners L.P.'>NMM</a> <font color='green'>+10%</font>&nbsp;on sale of one containership and options to sell four additional containerships.</li><li><a href='https://seekingalpha.com/symbol/LYL' title='Dragon Victory International Limited'>LYL</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/AVLR' title='Avalara'>AVLR</a> <font color='green'>+8%</font>&nbsp;<a href=\"https://seekingalpha.com/news/3364331-avalara-starts-first-day-trade-46-percent\" target=\"_blank\">extends</a>&nbsp;last week run.</li><li><a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+6%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/pr/17194138-immunogen-announces-fda-fast-track-designation-mirvetuximab-soravtansine-patients-platinum\" target=\"_blank\">approved</a> Fast Track designation for its lead program, mirvetuximab soravtansine.</li><li><a href='https://seekingalpha.com/symbol/JD' title='JD.com'>JD</a> <font color='green'>+5%</font>&nbsp;on big Google <a href=\"https://seekingalpha.com/news/3364459-big-google-investment-jd-com\" target=\"_blank\">investment</a>.</li><li><a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3364491-geron-shows-positive-effect-phase-2-3-mds-study-shares-5-percent-premarket\" target=\"_blank\">positive</a> effect in Phase 2/3 MDS study.</li><li><a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364546\" data-linked=\"Premarket Gainers as of 9:05 am (06/18/2018)\" data-tweet=\"$PTCT $PTCT $CBPO - Premarket Gainers as of 9:05 am (06/18/2018) https://seekingalpha.com/news/3364546-premarket-gainers-of-9-05-06-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364546-premarket-gainers-of-9-05-06-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364543\" data-ts=\"1529328269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMM\" target=\"_blank\">NMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364543-navios-maritime-partners-sells-containership-for-36m-options-four\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navios Maritime Partners sells containership for $36M, options four more</a></h4><ul>     <li>Navios Maritime Partners (NYSE:<a href='https://seekingalpha.com/symbol/NMM' title='Navios Maritime Partners L.P.'>NMM</a>) <font color='green'>+9.5%</font> premarket after announcing following Friday's close that it has <a href=\"https://seekingalpha.com/pr/17193711-navios-maritime-partners-l-p-announces-sale-one-containership-options-sell-four-additional\" target=\"_blank\">agreed to sell</a> the <em>Hyundai Hongkong</em> 6,800 TEU containership to Navios Maritime Containers for $36M.</li>     <li>NMM also grants options to Navios Containers to acquire four similar additional containerships for $36M/vessel.</li><li>Following the sale, NMM  controls a fleet of 37 vessels: 13 Capesize vessels, 17 Panamaxes, three Ultra-Handymaxes and four Container  vessels.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364543\" data-linked=\"Navios Maritime Partners sells containership for $36M, options four more\" data-tweet=\"$NMM - Navios Maritime Partners sells containership for $36M, options four more https://seekingalpha.com/news/3364543-navios-maritime-partners-sells-containership-for-36m-options-four?source=tweet\" data-url=\"https://seekingalpha.com/news/3364543-navios-maritime-partners-sells-containership-for-36m-options-four\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364541\" data-ts=\"1529328025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBSV\" target=\"_blank\">OBSV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364541-obseva-up-34-premarket-on-successful-mid-stage-linzagolix-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ObsEva up 34% premarket on successful mid-stage linzagolix study</a></h4><ul><li>Thinly traded ObsEva SA (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a>) is up&nbsp;<font color='green'>34%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17194023-obseva-sa-achieves-primary-secondary-endpoints-edelweiss-phase-2b-clinical-trial-linzagolix\" target=\"_blank\">announcement </a>of positive results from a Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02778399?titles=edelweiss&amp;lead=obseva&amp;rank=1\" target=\"_blank\">EDELWEISS</a>, evaluating linzagolix for the treatment of endometriosis-associated pain.</li><li>The study met the primary endpoint of a statistically significant proportion of responders (56.3 - 61.5% depending on the dose) compared to placebo (34.5%).</li><li>Key secondary endpoints were also met.</li><li>Phase 3 studies are next up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364541\" data-linked=\"ObsEva up 34% premarket on successful mid-stage linzagolix study\" data-tweet=\"$OBSV - ObsEva up 34% premarket on successful mid-stage linzagolix study https://seekingalpha.com/news/3364541-obseva-up-34-premarket-on-successful-mid-stage-linzagolix-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3364541-obseva-up-34-premarket-on-successful-mid-stage-linzagolix-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364536\" data-ts=\"1529327345\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364536-premarket-losers-of-9-05-6-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (6/18/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>&nbsp;<font color='red'>-51%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3364509-catalyst-bio-33-percent-premarket-appearance-neutralizing-abs-cb-2679d-isu304-hemophilia-b\" target=\"_blank\">providing</a> update on CB 2679d/ISU304 factor IX clinical program in Hemophilia B.</li><li><a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>&nbsp;<font color='red'>-7%</font>&nbsp;on likely <a href=\"https://seekingalpha.com/news/3364520-ziopharm-12-percent-premarket-likely-delay-phase-1-car-t-study\" target=\"_blank\">delay</a> in Phase 1 CAR-T study.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364536\" data-linked=\"Premarket Losers as of 9:05 am (6/18/2018)\" data-tweet=\"$CBIO $CBIO $ZIOP - Premarket Losers as of 9:05 am (6/18/2018) https://seekingalpha.com/news/3364536-premarket-losers-of-9-05-6-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364536-premarket-losers-of-9-05-6-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364534\" data-ts=\"1529327165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364534-fda-rejects-valeants-application-for-psoriasis-lotion-duobrii-shares-down-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects Valeant&#39;s application for psoriasis lotion Duobrii; shares down 5% premarket</a></h4><ul><li>Valeant Pharmaceuticals (VRX) slips&nbsp;<font color='red'>5%</font>&nbsp;premarket on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/17194064-fda-issues-complete-response-letter-duobrii-halobetasol-propionate-tazarotene-lotion\" target=\"_blank\">announcement </a>that it received a CRL from the FDA regarding its marketing application for topical plaque psoriasis med DUOBRII (halobetasol propionate and tazarotene) lotion.</li><li>The CRL cited questions regarding pharmacokinetic data. No deficiencies in efficacy, safety or CMC processes were noted.</li><li>The company says it plans to resolve the issue as soon as possible.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364534\" data-linked=\"FDA rejects Valeant&#39;s application for psoriasis lotion Duobrii; shares down 5% premarket\" data-tweet=\"$BHC - FDA rejects Valeant&#39;s application for psoriasis lotion Duobrii; shares down 5% premarket https://seekingalpha.com/news/3364534-fda-rejects-valeants-application-for-psoriasis-lotion-duobrii-shares-down-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3364534-fda-rejects-valeants-application-for-psoriasis-lotion-duobrii-shares-down-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>228&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364527\" data-ts=\"1529326483\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CATS\" target=\"_blank\">CATS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364527-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Catasys (NASDAQ:<a href='https://seekingalpha.com/symbol/CATS' title='Catasys Inc.'>CATS</a>) initiated with Buy rating and $10 (16% upside) price target at Canaccord Genuity. Shares up&nbsp;<font color='green'>1%</font>&nbsp;premarket.</li><li>Kiniksa Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KNSA' title='Kiniksa Pharmaceuticals'>KNSA</a>) initiated with Overweight rating and $29 (59% upside) price target at JPMorgan. Initiated with Neutral rating and $22 price target at Goldman Sachs. Initiated with Market Outperform rating at JMP Securities. Initiated with Outperform rating and $31 price target at Wedbush.</li><li>Scholar Rock Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/SRRK' title='Scholar Rock Holding'>SRRK</a>) initiated with Outperform rating and $31 (65%) price target at BMO. Initiated with Buy rating and $26 price target at Jefferies. Initiated with Outperform rating at Cowen and Company. Initiated with Outperform rating and $25 price target at Wedbush. Shares up a fraction premarket.</li><li>Tandem Diabetes Care (NASDAQ:<a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a>) initiated with Buy rating and $30 (51% upside) at Lake Street. Shares up a fraction premarket.</li><li>IQVIA (NYSE:<a href='https://seekingalpha.com/symbol/IQV' title='IQVIA Holdings, Inc.'>IQV</a>) upgraded to Outperform at Baird.</li><li>PTC Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a>) upgraded to Outperform with a $48 (29% upside) price target at RBC. Upgraded to Outperform at William Blair. Shares up&nbsp;<font color='green'>37%&nbsp;</font>premarket.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) upgraded to Market Perform at Wells Fargo. Shares down&nbsp;<font color='red'>1%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364527\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$CATS $CATS $KNSA - Premarket analyst action - healthcare https://seekingalpha.com/news/3364527-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3364527-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364524\" data-ts=\"1529325758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364524-verastems-duvelisib-shows-significant-treatment-effect-in-cll-study-shares-up-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verastem&#39;s duvelisib shows significant treatment effect in CLL study; shares up 14% premarket</a></h4><ul><li>Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) is up&nbsp;<font color='green'>14%</font>&nbsp;premarket on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/17193812-verastem-oncology-presents-duvelisib-data-eha-2018-annual-meeting\" target=\"_blank\">announcement </a>of positive results from a Phase 1b/2 clinical trial assessing duvelisib, combined with a chemo regimen called <a href=\"http://chemocare.com/chemotherapy/acronyms/fcr.aspx\" target=\"_blank\">FCR</a>, for the first-line treatment in younger patients with chronic lymphocytic leukemia &#40;CLL&#41;. The data were presented at EHA in Stockholm.</li><li>The objective response rate was 94% with 76% of patients achieving bone marrow minimal residual disease &#40;MRD&#41; negativity. The complete response rate was 26% and the partial response rate was 68%.</li><li>Data from the crossover extension phase of the Phase 3 DUO study in patients with treatment-resistant CLL/small lymphocytic lymphoma &#40;SLL&#41; showed an ORR of 73%.</li><li>Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3328840-verastem-submits-u-s-marketing-application-lead-candidate-duvelisib-shares-ahead-7-percent\" target=\"_blank\">Verastem submits U.S. marketing application for lead candidate duvelisib; shares ahead 7% premarket</a> (Feb. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364524\" data-linked=\"Verastem&#39;s duvelisib shows significant treatment effect in CLL study; shares up 14% premarket\" data-tweet=\"$VSTM - Verastem&#39;s duvelisib shows significant treatment effect in CLL study; shares up 14% premarket https://seekingalpha.com/news/3364524-verastems-duvelisib-shows-significant-treatment-effect-in-cll-study-shares-up-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3364524-verastems-duvelisib-shows-significant-treatment-effect-in-cll-study-shares-up-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364522\" data-ts=\"1529325465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBOT\" target=\"_blank\">MBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364522-epo-grants-microbot-patent-for-device-to-prevent-shunt-stenosis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EPO grants Microbot patent for device to prevent shunt stenosis</a></h4><ul> <li>European Patent Office &#40;EPO&#41; will <a href=\"https://seekingalpha.com/pr/17193998-microbot-medical-inc-announces-european-patent-offices-intent-grant-patent-device-prevention\" target=\"_blank\">grant</a> Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a>) a patent for Application No. 12837337.0, covering a device for the prevention of stenosis in blood vessels, especially for use on blood vessels adjacent to a hemodialysis shunt.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3273391-microbot-medical-continues-solidify-ip-portfolio-us-patent-device-preventing-shunt-stenosis\" target=\"_blank\">Microbot Medical continues to solidify IP portfolio with US patent for device for preventing shunt stenosis; shares are ahead 12% premarket</a> (June 14, 2017)</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3364522\" data-linked=\"EPO grants Microbot patent for device to prevent shunt stenosis\" data-tweet=\"$MBOT - EPO grants Microbot patent for device to prevent shunt stenosis https://seekingalpha.com/news/3364522-epo-grants-microbot-patent-for-device-to-prevent-shunt-stenosis?source=tweet\" data-url=\"https://seekingalpha.com/news/3364522-epo-grants-microbot-patent-for-device-to-prevent-shunt-stenosis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364521\" data-ts=\"1529325199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LDOS\" target=\"_blank\">LDOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364521-leidosminus-2-on-goldman-downgrade-18-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leidos -2% on Goldman downgrade with 18% upside</a></h4><ul><li>        Goldman <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Leidos+Holdings+%28LDOS%29+to+Neutral/14314504.html\" target=\"_blank\">downgrades</a> Leidos (NYSE:<a href='https://seekingalpha.com/symbol/LDOS' title='Leidos Holdings, Inc.'>LDOS</a>) from Buy to Neutral.</li><li>               Price target drops from $82 to $71, an 18% upside to Friday&rsquo;s close. &nbsp;&nbsp;</li><li>               Leidos shares are&nbsp;<font color='red'>down 2%</font>&nbsp;premarket to $58.98.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3364521\" data-linked=\"Leidos -2% on Goldman downgrade with 18% upside\" data-tweet=\"$LDOS - Leidos -2% on Goldman downgrade with 18% upside https://seekingalpha.com/news/3364521-leidosminus-2-on-goldman-downgrade-18-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3364521-leidosminus-2-on-goldman-downgrade-18-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364520\" data-ts=\"1529324800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364520-ziopharm-down-12-premarket-on-likely-delay-in-phase-1-car-t-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm down 12% premarket on likely delay in Phase 1 CAR-T study</a></h4><ul><li>Ziopharm (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) is down&nbsp;<font color='red'>12%</font>&nbsp;premarket on light volume in response to the <a href=\"https://seekingalpha.com/pr/17194043-ziopharm-oncology-reports-status-investigational-new-drug-application-phase-1-trial-evaluate\" target=\"_blank\">news </a>that the FDA has instituted a clinical hold on a Phase 1 clinical trial assessing CAR-T cells manufactured with its <em>Sleeping Beauty</em> technology in patients with treatment-resistant CD19+ leukemias and lymphomas.</li><li>The agency has requested additional information related to Chemistry, Manufacturing and Controls &#40;CMC&#41;. The company says the initiation of the study will likely be delayed.</li><li>Sleeping Beauty is a non-viral approach to engineer CAR+ and T cells that enables point-of-care manufacturing which, according to the company, should lower costs and broaden the applicability of CAR-T therapy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364520\" data-linked=\"Ziopharm down 12% premarket on likely delay in Phase 1 CAR-T study\" data-tweet=\"$ZIOP - Ziopharm down 12% premarket on likely delay in Phase 1 CAR-T study https://seekingalpha.com/news/3364520-ziopharm-down-12-premarket-on-likely-delay-in-phase-1-car-t-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3364520-ziopharm-down-12-premarket-on-likely-delay-in-phase-1-car-t-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364519\" data-ts=\"1529324795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZG\" target=\"_blank\">ZG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364519-zillowminus-2_8-goldman-steps-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zillow -2.8% as Goldman steps to sidelines</a></h4><ul><li>        Goldman <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Zillow+Group+%28ZG%29+to+Neutral/14314535.html\" target=\"_blank\">downgrades</a> Zillow (NASDAQ:<a href='https://seekingalpha.com/symbol/ZG' title='Zillow Group, Inc.'>ZG</a>) from Buy to Neutral.</li><li>                  Zillow Group shares are&nbsp;<font color='red'>down 2.8%&nbsp;</font>premarket to $63.40.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3364519\" data-linked=\"Zillow -2.8% as Goldman steps to sidelines\" data-tweet=\"$ZG - Zillow -2.8% as Goldman steps to sidelines https://seekingalpha.com/news/3364519-zillowminus-2_8-goldman-steps-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3364519-zillowminus-2_8-goldman-steps-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364516\" data-ts=\"1529324468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364516-coupa-softwareminus-2_7-btig-goes-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa Software -2.7% as BTIG goes Neutral</a></h4><ul><li>        BTIG <a href=\"https://www.streetinsider.com/Downgrades/BTIG+Downgrades+Coupa+Software+%28COUP%29+to+Neutral%2C+Says+NT+Upside+is+Largely+Realized+Now/14314715.html\" target=\"_blank\">downgrades</a> Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>) from Buy to Neutral.</li><li>               Coupa Software shares are&nbsp;<font color='red'>down 2.7%</font>&nbsp;premarket to $61.70.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3364516\" data-linked=\"Coupa Software -2.7% as BTIG goes Neutral\" data-tweet=\"$COUP - Coupa Software -2.7% as BTIG goes Neutral https://seekingalpha.com/news/3364516-coupa-softwareminus-2_7-btig-goes-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3364516-coupa-softwareminus-2_7-btig-goes-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364512\" data-ts=\"1529324094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDFN\" target=\"_blank\">RDFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364512-redfinminus-4_7-goldman-moves-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Redfin -4.7% as Goldman moves to Sell</a></h4><ul><li>        Goldman Sachs downgrades Redfin (NASDAQ:<a href='https://seekingalpha.com/symbol/RDFN' title='Redfin'>RDFN</a>) from Neutral to Sell.</li><li>               Redfin shares are&nbsp;<font color='red'>down 4.7%</font>&nbsp;premarket to $22.90.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3364512\" data-linked=\"Redfin -4.7% as Goldman moves to Sell\" data-tweet=\"$RDFN - Redfin -4.7% as Goldman moves to Sell https://seekingalpha.com/news/3364512-redfinminus-4_7-goldman-moves-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3364512-redfinminus-4_7-goldman-moves-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364507\" data-ts=\"1529323630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIBB\" target=\"_blank\">HIBB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364507-hibbett-sportsminus-4-after-two-notch-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hibbett Sports -4% after two-notch downgrade</a></h4><ul> <li>Shares of Hibbett Sports (NASDAQ:<a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a>) drop in premarket trading after Bank of America Merrill Lunch downgrades the retailer to an Underperform rating in a two-notch move straight down from a Buy rating.</li> <li>BAML assigns a new price target of $20 on Hibbett.</li> <li>HIBB <font color='red'>-4.39%</font> premarket to $20.80.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3364507\" data-linked=\"Hibbett Sports -4% after two-notch downgrade\" data-tweet=\"$HIBB - Hibbett Sports -4% after two-notch downgrade https://seekingalpha.com/news/3364507-hibbett-sportsminus-4-after-two-notch-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3364507-hibbett-sportsminus-4-after-two-notch-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364499\" data-ts=\"1529322944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364499-ptc-therapeutics-risdiplam-shows-positive-effect-in-sma-study-shares-up-36-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTC Therapeutics&#39; risdiplam shows positive effect in SMA study; shares up 36% premarket</a></h4><ul><li>PTC Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a>) is up&nbsp;<font color='green'>36%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17193827-updated-preliminary-data-sma-firefish-program-type-1-babies-presented-curesma-conference\" target=\"_blank\">announcement </a>of positive results from its open-label FIREFISH study evaluating risdiplam (RG7916) in babies with Type 1 spinal muscular atrophy &#40;SMA&#41;. The data were presented at the Annual SMA Researcher Meeting in Dallas, TX.</li><li>Over 90% of SMA babies treated with risdiplam, a splicing modifier that targets the survival motor neuron 2 RNA, achieved more than a four-point increase in a test of motor skills called CHOP-INTEND. The median increase was 5.5 points.</li><li>The company says babies with Type 1 SMA typically do not experience functional motor milestone improvements based on natural history.</li><li>Related tickers: (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>)(<font color='red'>-2%</font>&nbsp;premarket) (NASDAQ:<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a>) (<font color='red'>-5%</font>&nbsp;premarket)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364499\" data-linked=\"PTC Therapeutics&#39; risdiplam shows positive effect in SMA study; shares up 36% premarket\" data-tweet=\"$PTCT $PTCT $BIIB - PTC Therapeutics&#39; risdiplam shows positive effect in SMA study; shares up 36% premarket https://seekingalpha.com/news/3364499-ptc-therapeutics-risdiplam-shows-positive-effect-in-sma-study-shares-up-36-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3364499-ptc-therapeutics-risdiplam-shows-positive-effect-in-sma-study-shares-up-36-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364496\" data-ts=\"1529322159\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QTNT\" target=\"_blank\">QTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364496-quotient-reports-concordance-data-from-mosaiq-european-field-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quotient reports concordance data from the MosaiQ European field trial</a></h4><ul> <li>Quotient Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a>) <a href=\"https://seekingalpha.com/pr/17193943-quotient-limited-reports-concordance-data-mosaiq-european-field-trial\" target=\"_blank\">reports</a> concordance data for the initial MosaiQ blood grouping microarray generated in its European field trial, which exceeded the targeted criteria for submission for CE marking.</li>  <li>Under the terms of the indenture governing its 12% Senior Secured Notes due 2023, Quotient plans to issue an additional $36M of notes with funding to occur within next 10 business days.&nbsp;The purchasers will also be allocated an additional 0.6% royalty right on net sales of MosaiQ instruments and microarrays.</li><li>Shares are up&nbsp;<font color='green'>11%</font>&nbsp;premarket.</li>            </ul><div class=\"tiny-share-widget\" data-id=\"3364496\" data-linked=\"Quotient reports concordance data from the MosaiQ European field trial\" data-tweet=\"$QTNT - Quotient reports concordance data from the MosaiQ European field trial https://seekingalpha.com/news/3364496-quotient-reports-concordance-data-from-mosaiq-european-field-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3364496-quotient-reports-concordance-data-from-mosaiq-european-field-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364492\" data-ts=\"1529321456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364492-intelminus-1_3-on-analyst-downgrade-18-downside-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel -1.3% on analyst downgrade with 18% downside (update)</a></h4><ul><li>Northland Capital <a href=\"https://www.streetinsider.com/Analyst+Comments/Northland+Capital+Markets+Downgrades+Intel+%28INTC%29+to+Underperform/14314813.html\" target=\"_blank\">downgrades</a> Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) from Market Perform to Underperform.</li><li>Price target: $45, an 18% downside to Friday&rsquo;s close.</li><li>Intel shares are&nbsp;<font color='red'>down 1.3%</font>&nbsp;premarket to $54.40.</li><li>        Update with <a href=\"https://www.cnbc.com/2018/06/18/intel-shares-fall-after-small-wall-street-firm-downgrades-chipmaker-predicting-slower-growth.html\" target=\"_blank\">more information</a> on the downgrade:</li><li>               Analyst Gus Richard expects Intel&rsquo;s data center sales growth to slow starting in Q3 due to no clear catalyst after Q2 earnings and rising competition from AMD (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+4.9%</font>) and Nvidia (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='red'>-0.6%</font>).&nbsp;</li><li>               Richard forecasts that Intel&rsquo;s data center sales growth will peak at 25% in Q2 then drop to 20% in Q3 and 11% in Q4.&nbsp;</li><li>               Intel shares are now&nbsp;<font color='red'>down 4.2%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3364492\" data-linked=\"Intel -1.3% on analyst downgrade with 18% downside (update)\" data-tweet=\"$INTC $INTC $AMD - Intel -1.3% on analyst downgrade with 18% downside (update) https://seekingalpha.com/news/3364492-intelminus-1_3-on-analyst-downgrade-18-downside-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3364492-intelminus-1_3-on-analyst-downgrade-18-downside-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364491\" data-ts=\"1529321293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GERN\" target=\"_blank\">GERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364491-geron-shows-positive-effect-in-phase-2-3-mds-study-shares-up-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Geron shows positive effect in Phase 2/3 MDS study; shares up 5% premarket</a></h4><ul><li>Geron (NASDAQ:<a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a>) is up&nbsp;<font color='green'>5%&nbsp;</font>premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17193960-geron-reports-imetelstat-oral-presentation-european-hematology-association-congress\" target=\"_blank\">announcement </a>of positive results from a Phase 2/3 clinical trial, iMerge, evaluating imetelstat in lower-risk myelodysplastic syndromes &#40;MDS&#41;. The data were presented at EHA in Stockholm.</li><li>In 32 red blood cell transfusion-dependent patients at baseline, 34% (n=11/32) achieved transfusion independence &#40;TI&#41; for at least eight weeks with a median duration of TI of 23.1 weeks. 16% (n=5/32) achieved TI for at least 24 weeks with a median duration of more than one year.</li><li>Average relative reduction in transfusion burden from baseline was 60%.</li><li><a href=\"http://www.geron.com/imetelstat\" target=\"_blank\">Imetelstat&nbsp;</a>inhibits an enzyme called telomerase by binding to its RNA template. Most cancers have a high level of telomerase activity and relatively short&nbsp;<a href=\"https://www.tasciences.com/what-is-a-telomere/\" target=\"_blank\">telemeres&nbsp;</a>(caps at the end of each strand of DNA) compared to normal cells. Inhibiting telomerase inhibits the proliferation of malignant progenitor cells.</li><li>The company expects a decision from licensee Janssen next quarter on whether it will continue development of imetelstat.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364491\" data-linked=\"Geron shows positive effect in Phase 2/3 MDS study; shares up 5% premarket\" data-tweet=\"$GERN - Geron shows positive effect in Phase 2/3 MDS study; shares up 5% premarket https://seekingalpha.com/news/3364491-geron-shows-positive-effect-in-phase-2-3-mds-study-shares-up-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3364491-geron-shows-positive-effect-in-phase-2-3-mds-study-shares-up-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>108&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364485\" data-ts=\"1529320331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBPO\" target=\"_blank\">CBPO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364485-china-biologic-products-up-16-premarket-on-110-share-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Biologic Products up 16% premarket on $110/share offer</a></h4><ul><li>China Biologic Products (NASDAQ:<a href='https://seekingalpha.com/symbol/CBPO' title='China Biologic Products, Inc.'>CBPO</a>) is up&nbsp;<font color='green'>16%</font>&nbsp;premarket on light volume in response to the <a href=\"https://www.reuters.com/article/us-china-biologic-m-a-ccre-holdings/investment-firm-citic-capital-offers-to-buy-china-biologic-products-idUSKBN1JE11D\" target=\"_blank\">news </a>that it has received a $110/share cash bid from shareholder CITIC Capital Holdings that values the company at $3.65B.</li><li><strong>Update</strong>: On June 19, the company <a href=\"https://seekingalpha.com/pr/17195385-china-biologic-announces-receipt-non-binding-acquisition-proposal\" target=\"_blank\">confirmed </a>the receipt of the offer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364485\" data-linked=\"China Biologic Products up 16% premarket on $110/share offer\" data-tweet=\"$CBPO - China Biologic Products up 16% premarket on $110/share offer https://seekingalpha.com/news/3364485-china-biologic-products-up-16-premarket-on-110-share-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3364485-china-biologic-products-up-16-premarket-on-110-share-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364480\" data-ts=\"1529319594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLDB\" target=\"_blank\">SLDB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364480-solid-biosciences-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Solid Biosciences halted pending news</a></h4><ul><li>Nasdaq has <a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspended trading</a> in Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences, Inc.'>SLDB</a>) pending the release of news.</li><li><strong>Update</strong>: The FDA has <a href=\"https://seekingalpha.com/pr/17193980-solid-biosciences-announces-fda-removes-clinical-hold-sgtminus-001\" target=\"_blank\">removed </a>the clinical hold on its Phase 1/2 clinical trial assessing SGT-001 for the treatment of Duchenne muscular dystrophy &#40;DMD&#41;. Enrollment will resume as soon as possible. The study was suspended in March after the first patient experienced an adverse event.</li><li>Shares will resume trading at 7:30 am ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339432-fda-places-solid-biosciences-dmd-study-lead-candidate-sgtminus-001-clinical-hold-due-adverse\" target=\"_blank\">FDA places Solid Biosciences' DMD study of lead candidate SGT-001 on clinical hold due to adverse event in first patient; shares down 57% premarket</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364480\" data-linked=\"Solid Biosciences halted pending news\" data-tweet=\"$SLDB - Solid Biosciences halted pending news https://seekingalpha.com/news/3364480-solid-biosciences-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3364480-solid-biosciences-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 AM </div></div></li>","count":70,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}